Advertisement

Cannabiskonsum zum Freizeitgebrauch

  • Miriam Schneider
  • Chris Maria Friemel
  • Rupert von Keller
  • Kristina Adorjan
  • Udo Bonnet
  • Alkomiet Hasan
  • Derik Hermann
  • Joseph Kambeitz
  • Dagmar Koethe
  • Ludwig Kraus
  • F. Markus Leweke
  • Beat Lutz
  • Liane Paul
  • Oliver Pogarell
  • Ulrich Preuss
  • Michael Schäfer
  • Sophia Schmieder
  • Roland Simon
  • Martin Storr
  • Eva Hoch

Zusammenfassung

Zur gezielten Aufnahme, Verarbeitung und Speicherung der komplexen sensorischen Informationen unserer Umwelt benötigen wir kognitive Fähigkeiten. Unter „Kognition” versteht man dabei eine Vielzahl bewusster sowie unbewusster neuronaler Prozesse des Gehirns, die bei der Verarbeitung externer und interner Informationen ablaufen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. [1]
    Abush H, Akirav I (2012) Short- and long-term cognitive effects of chronic cannabinoids administration in late-adolescence rats. PloS one 7 (2): e31731. doi: 10.1371/journal.pone.0031731
  2. [2]
    Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS (2010) Sex, drugs, and cognition: effects of marijuana. J Psychoact Drugs 42 (4): 413–424. doi: 10.1080/02791072.2010.10400704
  3. [3]
    Batalla A, Bhattacharyya S, Yucel M, Fusar-Poli P, Crippa JA, Nogue S, Torrens M, Pujol J, Farre M, Martin-Santos R (2013) Structural and functional imaging studies in chronic cannabis users: a systematic review of adolescent and adult findings. PloS one 8 (2): e55821. doi: 10.1371/journal.pone.0055821
  4. [4]
    Bolla KI, Eldreth DA, Matochik JA, Cadet JL (2005) Neural substrates of faulty decision-making in abstinent marijuana users. NeuroImage 26 (2): 480–492. doi: 10.1016/j.neuroimage.2005.02.012
  5. [5]
    Borgwardt SJ, Allen P, Bhattacharyya S, Fusar-Poli P, Crippa JA, Seal ML, Fraccaro V, Atakan Z, Martin-Santos R, O’Carroll C, Rubia K, McGuire PK (2008) Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biol Psychiat 64 (11): 966–973. doi: 10.1016/j.biopsych.2008.05.011
  6. [6]
    Broyd SJ, van Hell HH, Beale C, Yucel M, Solowij N (2016) Acute and Chronic Effects of Cannabinoids on Human Cognition-A Systematic Review. Biol Psychiat 79 (7): 557–567. doi: 10.1016/j.biopsych.2015.12.002
  7. [7]
    Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y (2012) Endocannabinoid signaling and synaptic function. Neuron 76 (1): 70–81. doi: 10.1016/j.neuron.2012.09.020
  8. [8]
    Chan RC, Wang Y, Ma Z, Hong XH, Yuan Y, Yu X, Li Z, Shum D, Gong QY (2008) Objective measures of prospective memory do not correlate with subjective complaints in schizophrenia. Schizophr Res 103 (1–3): 229–239. doi: 10.1016/j.schres.2008.02.019
  9. [9]
    Chang L, Yakupov R, Cloak C, Ernst T (2006) Marijuana use is associated with a reorganized visual-attention network and cerebellar hypoactivation. Brain 129 (Pt 5): 1096–1112. doi: 10.1093/brain/awl064
  10. [10]
    Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009
  11. [11]
    Crane NA, Schuster RM, Gonzalez R (2013) Preliminary evidence for a sex-specific relationship between amount of cannabis use and neurocognitive performance in young adult cannabis users. JINS 19 (9): 1009–1015. doi: 10.1017/s135561771300088X
  12. [12]
    D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29 (8): 1558–1572. doi: 10.1038/sj.npp.1300496
  13. [13]
    D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008) Blunted psychotomimetic and amnestic effects of delta-9-tetrahydrocannabinol in frequent users of cannabis. Neuropsychopharmacology 33 (10): 2505–2516. doi: 10.1038/sj.npp.1301643
  14. [14]
    De Bellis MD, Wang L, Bergman SR, Yaxley RH, Hooper SR, Huettel SA (2013) Neural mechanisms of risky decision-making and reward response in adolescent onset cannabis use disorder. Drug Alcohol Depend 133 (1): 134–145. doi: 10.1016/j.drugalcdep.2013.05.020
  15. [15]
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004
  16. [16]
    Englund A, Morrison PD, Nottage J, Hague D, Kane F, Bonaccorso S, Stone JM, Reichenberg A, Brenneisen R, Holt D, Feilding A, Walker L, Murray RM, Kapur S (2013) Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol (Oxford, England) 27 (1): 19–27. doi: 10.1177/0269881112460109
  17. [17]
    Fontes MA, Bolla KI, Cunha PJ, Almeida PP, Jungerman F, Laranjeira RR, Bressan RA, Lacerda AL (2011) Cannabis use before age 15 and subsequent executive functioning. Br J Psychiat 198 (6): 442–447. doi: 10.1192/bjp.bp.110.077479
  18. [18]
    Freund TF, Katona I, Piomelli D (2003) Role of endogenous cannabinoids in synaptic signaling. Physiol Rev 83 (3): 1017–1066. doi: 10.1152/physrev.00004.2003
  19. [19]
    Fridberg DJ, Queller S, Ahn W-Y, Kim W, Bishara AJ, Busemeyer JR, Porrino L, Stout JC (2010) Cognitive mechanisms underlying risky decision-making in chronic cannabis users. J Math Psychol 54 (1): 28–38. doi: https://doi.org/10.1016/j.jmp.2009.10.002
  20. [20]
    Fried PA, Watkinson B, Gray R (2005) Neurocognitive consequences of marihuana—a comparison with pre-drug performance. Neurotoxicol Teratol 27 (2): 231–239. doi: 10.1016/j.ntt.2004.11.003
  21. [21]
    Ganzer F, Broning S, Kraft S, Sack PM, Thomasius R (2016) Weighing the Evidence: A Systematic Review on Long-Term Neurocognitive Effects of Cannabis Use in Abstinent Adolescents and Adults. Neuropsychol Rev 26 (2): 186–222. doi: 10.1007/s11065-016-9316-2
  22. [22]
    Gruber SA, Dahlgren MK, Sagar KA, Gonenc A, Killgore WD (2012) Age of onset of marijuana use impacts inhibitory processing. Neurosci Lett 511 (2): 89–94. doi: 10.1016/j.neulet.2012.01.039
  23. [23]
    Han J, Kesner P, Metna-Laurent M, Duan T, Xu L, Georges F, Koehl M, Abrous DN, Mendizabal-Zubiaga J, Grandes P, Liu Q, Bai G, Wang W, Xiong L, Ren W, Marsicano G, Zhang X (2012) Acute cannabinoids impair working memory through astroglial CB1 receptor modulation of hippocampal LTD. Cell 148 (5): 1039–1050. doi: 10.1016/j.cell.2012.01.037
  24. [24]
    Hanson KL, Thayer RE, Tapert SF (2014) Adolescent marijuana users have elevated risk-taking on the balloon analog risk task. J Psychopharmacol (Oxford, England) 28 (11): 1080–1087. doi: 10.1177/0269881114550352
  25. [25]
    Harvey MA, Sellman JD, Porter RJ, Frampton CM (2007) The relationship between non-acute adolescent cannabis use and cognition. Drug Alcohol Rev 26 (3): 309–319. doi: 10.1080/09595230701247772
  26. [26]
    Hebert-Chatelain E, Desprez T, Serrat R, Bellocchio L, Soria-Gomez E, Busquets-Garcia A, Pagano Zottola AC, Delamarre A, Cannich A, Vincent P, Varilh M, Robin LM, Terral G, Garcia-Fernandez MD, Colavita M, Mazier W, Drago F, Puente N, Reguero L, Elezgarai I, Dupuy JW, Cota D, Lopez-Rodriguez ML, Barreda-Gomez G, Massa F, Grandes P, Benard G, Marsicano G (2016) A cannabinoid link between mitochondria and memory. Nature 539 (7630): 555–559. doi: 10.1038/nature20127
  27. [27]
    Hermann D, Schneider M (2012) Potential protective effects of cannabidiol on neuroanatomical alterations in cannabis users and psychosis: a critical review. Curr Pharmaceut Design 18 (32): 4897–4905Google Scholar
  28. [28]
    Hester R, Nestor L, Garavan H (2009) Impaired error awareness and anterior cingulate cortex hypoactivity in chronic cannabis users. Neuropsychopharmacology 34 (11): 2450–2458. doi: 10.1038/npp.2009.67
  29. [29]
    Hu SS, Mackie K (2015) Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol 231: 59–93. doi: 10.1007/978-3-319-20825-1_3
  30. [30]
    Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4 (8): 1770–1804. doi: 10.1002/cbdv.200790152
  31. [31]
    Iversen L (2003) Cannabis and the brain. Brain 126 (6): 1252–1270. doi: 10.1093/brain/awg143
  32. [32]
    Jackson NJ, Isen JD, Khoddam R, Irons D, Tuvblad C, Iacono WG, McGue M, Raine A, Baker LA (2016) Impact of adolescent marijuana use on intelligence: Results from two longitudinal twin studies. Proc Natl Acad Sci USA 113 (5): E500–508. doi: 10.1073/pnas.1516648113
  33. [33]
    Jacobsen LK, Pugh KR, Constable RT, Westerveld M, Mencl WE (2007) Functional correlates of verbal memory deficits emerging during nicotine withdrawal in abstinent adolescent cannabis users. Biol Psychiat 61 (1): 31–40. doi: 10.1016/j.biopsych.2006.02.014
  34. [34]
    Jacobus J, Goldenberg D, Wierenga CE, Tolentino NJ, Liu TT, Tapert SF (2012) Altered cerebral blood flow and neurocognitive correlates in adolescent cannabis users. Psychopharmacology 222 (4): 675–684. doi: 10.1007/s00213-012-2674-4
  35. [35]
    James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: 10.1016/j.pscychresns.2013.07.012
  36. [36]
    Kambeitz JP, Bhattacharyya S, Kambeitz-Ilankovic LM, Valli I, Collier DA, McGuire P (2012) Effect of BDNF val (66)met polymorphism on declarative memory and its neural substrate: a meta-analysis. Neurosci Biobehav Rev 36 (9): 2165–2177. doi: 10.1016/j.neubiorev.2012.07.002
  37. [37]
    Kano M, Ohno-Shosaku T, Hashimotodani Y, Uchigashima M, Watanabe M (2009) Endocannabinoid-mediated control of synaptic transmission. Physiol Rev 89 (1): 309–380. doi: 10.1152/physrev.00019.2008
  38. [38]
    Lane SD, Cherek DR, Tcheremissine OV, Steinberg JL, Sharon JL (2007) Response perseveration and adaptation in heavy marijuana-smoking adolescents. Addict Behav 32 (5): 977–990. doi: 10.1016/j.addbeh.2006.07.007
  39. [39]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  40. [40]
    Lisdahl KM, Price JS (2012) Increased marijuana use and gender predict poorer cognitive functioning in adolescents and emerging adults. JINS 18 (4): 678–688. doi: 10.1017/s1355617712000276
  41. [41]
    Lorenzetti V, Solowij N, Yucel M (2016) The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biol Psychiat 79 (7): e17–31. doi: 10.1016/j.biopsych.2015.11.013
  42. [42]
    Lutz B, Marsicano G, Maldonado R, Hillard CJ (2015) The endocannabinoid system in guarding against fear, anxiety and stress. Nature Rev Neurosci 16 (12): 705–718. doi: 10.1038/nrn4036
  43. [43]
    Lyons MJ, Bar JL, Panizzon MS, Toomey R, Eisen S, Xian H, Tsuang MT (2004) Neuropsychological consequences of regular marijuana use: a twin study. Psychol Med 34 (7): 1239–1250Google Scholar
  44. [44]
    Makela P, Wakeley J, Gijsman H, Robson PJ, Bhagwagar Z, Rogers RD (2006) Low doses of delta-9 tetrahydrocannabinol (THC) have divergent effects on short-term spatial memory in young, healthy adults. Neuropsychopharmacology 31 (2): 462–470. doi: 10.1038/sj.npp.1300871
  45. [45]
    Martin-Santos R, Fagundo AB, Crippa JA, Atakan Z, Bhattacharyya S, Allen P, Fusar-Poli P, Borgwardt S, Seal M, Busatto GF, McGuire P (2010) Neuroimaging in cannabis use: a systematic review of the literature. Psychol Med 40 (3): 383–398. doi: 10.1017/s0033291709990729
  46. [46]
    Mato S, Robbe D, Puente N, Grandes P, Manzoni OJ (2005) Presynaptic homeostatic plasticity rescues long-term depression after chronic Delta 9-tetrahydrocannabinol exposure. J Neurosci 25 (50): 11619–11627. doi: 10.1523/jneurosci.2294-05.2005
  47. [47]
    McQueeny T, Padula CB, Price J, Medina KL, Logan P, Tapert SF (2011) Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224 (1): 128–134. doi: 10.1016/j.bbr.2011.05.031
  48. [48]
    Medina KL, Hanson KL, Schweinsburg AD, Cohen-Zion M, Nagel BJ, Tapert SF (2007) Neuropsychological functioning in adolescent marijuana users: subtle deficits detectable after a month of abstinence. JINS 13 (5): 807–820. doi: 10.1017/s1355617707071032
  49. [49]
    Medina KL, McQueeny T, Nagel BJ, Hanson KL, Yang TT, Tapert SF (2009) Prefrontal cortex morphometry in abstinent adolescent marijuana users: subtle gender effects. Addict Biol 14 (4): 457–468. doi: 10.1111/j.1369-1600.2009.00166.x
  50. [50]
    Medina KL, Nagel BJ, Tapert SF (2010) Abnormal cerebellar morphometry in abstinent adolescent marijuana users. Psychiat Res 182 (2): 152–159. doi: 10.1016/j.pscychresns.2009.12.004
  51. [51]
    Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE (2012) Persistent cannabis users show neuropsychological decline from childhood to midlife. Proc Natl Acad Sci USA 109 (40): E2657–2664. doi: 10.1073/pnas.1206820109
  52. [52]
    Millan MJ, Agid Y, Brune M, Bullmore ET, Carter CS, Clayton NS, Connor R, Davis S, Deakin B, DeRubeis RJ, Dubois B, Geyer MA, Goodwin GM, Gorwood P, Jay TM, Joels M, Mansuy IM, Meyer-Lindenberg A, Murphy D, Rolls E, Saletu B, Spedding M, Sweeney J, Whittington M, Young LJ (2012) Cognitive dysfunction in psychiatric disorders: characteristics, causes and the quest for improved therapy. Nat Rev Drug Discov 11 (2): 141–168. doi: 10.1038/nrd3628
  53. [53]
    Mokrysz C, Landy R, Gage SH, Munafo MR, Roiser JP, Curran HV (2016) Are IQ and educational outcomes in teenagers related to their cannabis use? A prospective cohort study. J Psychopharmacol (Oxford, England) 30 (2): 159–168. doi: 10.1177/0269881115622241
  54. [54]
    Morgan CJ, Schafer G, Freeman TP, Curran HV (2010) Impact of cannabidiol on the acute memory and psychotomimetic effects of smoked cannabis: naturalistic study: naturalistic study [corrected]. Br J Psychiat 197 (4): 285–290. doi: 10.1192/bjp.bp.110.077503
  55. [55]
    O’Leary DS, Block RI, Koeppel JA, Flaum M, Schultz SK, Andreasen NC, Ponto LB, Watkins GL, Hurtig RR, Hichwa RD (2002) Effects of smoking marijuana on brain perfusion and cognition. Neuropsychopharmacology 26 (6): 802–816. doi: 10.1016/s0893-133X(01)00425-0
  56. [56]
    O’Leary DS, Block RI, Koeppel JA, Schultz SK, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD (2007) Effects of smoking marijuana on focal attention and brain blood flow. Human Psychopharmacol 22 (3): 135–148. doi: 10.1002/hup.832
  57. [57]
    O’Leary DS, Block RI, Turner BM, Koeppel J, Magnotta VA, Ponto LB, Watkins GL, Hichwa RD, Andreasen NC (2003) Marijuana alters the human cerebellar clock. Neuroreport 14 (8): 1145–1151. doi: 10.1097/01.wnr.0000075420.59944.20
  58. [58]
    OCEBM (2011) The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine, 2 edn. http://www.cebm.net/index.aspx?o = 5653,
  59. [59]
    Padula CB, Schweinsburg AD, Tapert SF (2007) Spatial working memory performance and fMRI activation interaction in abstinent adolescent marijuana users. Psychol Addict Behav 21 (4): 478–487. doi: 10.1037/0893-164X.21.4.478
  60. [60]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengrichGoogle Scholar
  61. [61]
    Pope HG, Jr., Jacobs A, Mialet JP, Yurgelun-Todd D, Gruber S (1997) Evidence for a sex-specific residual effect of cannabis on visuospatial memory. Psychother Psychosomat 66 (4): 179–184Google Scholar
  62. [62]
    Pope HG, Jr., Yurgelun-Todd D (1996) The residual cognitive effects of heavy marijuana use in college students. JAMA 275 (7): 521–527Google Scholar
  63. [63]
    Quickfall J, Crockford D (2006) Brain neuroimaging in cannabis use: a review. J Neuropsychiat Clin Neurosci 18 (3): 318–332. doi: 10.1176/jnp.2006.18.3.318
  64. [64]
    Quinn HR, Matsumoto I, Callaghan PD, Long LE, Arnold JC, Gunasekaran N, Thompson MR, Dawson B, Mallet PE, Kashem MA, Matsuda-Matsumoto H, Iwazaki T, McGregor IS (2008) Adolescent rats find repeated Delta (9)-THC less aversive than adult rats but display greater residual cognitive deficits and changes in hippocampal protein expression following exposure. Neuropsychopharmacology 33 (5): 1113–1126. doi: 10.1038/sj.npp.1301475
  65. [65]
    Raber JC, Elzinga S, Kaplan C (2015) Understanding dabs: contamination concerns of cannabis concentrates and cannabinoid transfer during the act of dabbing. J Toxicol Sci 40 (6): 797–803. doi: 10.2131/jts.40.797
  66. [66]
    Ranganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D’Souza DC (2012) Naltrexone does not attenuate the effects of intravenous Delta9-tetrahydrocannabinol in healthy humans. Int J Neuropsychopharmacol 15 (9): 1251–1264. doi: 10.1017/s1461145711001830
  67. [67]
    Renard J, Krebs MO, Jay TM, Le Pen G (2013) Longterm cognitive impairments induced by chronic cannabinoid exposure during adolescence in rats: a strain comparison. Psychopharmacology 225 (4): 781–790. doi: 10.1007/s00213-012-2865-z
  68. [68]
    Rubino T, Realini N, Braida D, Guidi S, Capurro V, Vigano D, Guidali C, Pinter M, Sala M, Bartesaghi R, Parolaro D (2009) Changes in hippocampal morphology and neuroplasticity induced by adolescent THC treatment are associated with cognitive impairment in adulthood. Hippocampus 19 (8): 763–772. doi: 10.1002/hipo.20554
  69. [69]
    Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263. doi: 10.1111/j.1369-1600.2008.00110.x
  70. [70]
    Schneider M (2013) Adolescence as a vulnerable period to alter rodent behavior. Cell tissue Res 354 (1): 99–106. doi: 10.1007/s00441-013-1581-2
  71. [71]
    Schneider M, Kasanetz F, Lynch DL, Friemel CM, Lassalle O, Hurst DP, Steindel F, Monory K, Schafer C, Miederer I, Leweke FM, Schreckenberger M, Lutz B, Reggio PH, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988. doi: 10.1523/jneurosci.1937-15.2015
  72. [72]
    Schneider M, Levant B, Reichel M, Gulbins E, Kornhuber J, Müller CP (2016) Lipids in psychiatric disorders and preventive medicine. Neurosci Biobehav Rev doi: https://doi.org/10.1016/j.neubiorev.2016.06.002
  73. [73]
    Schoedel KA, Chen N, Hilliard A, White L, Stott C, Russo E, Wright S, Guy G, Romach MK, Sellers EM (2011) A randomized, double-blind, placebo-controlled, crossover study to evaluate the subjective abuse potential and cognitive effects of nabiximols oromucosal spray in subjects with a history of recreational cannabis use. Human Psychopharmacol 26 (3): 224–236. doi: 10.1002/hup.1196
  74. [74]
    Schoeler T, Kambeitz J, Behlke I, Murray R, Bhattacharyya S (2016) The effects of cannabis on memory function in users with and without a psychotic disorder: findings from a combined meta-analysis. Psychol Med 46 (1): 177–188. doi: 10.1017/s0033291715001646
  75. [75]
    Schreiner AM, Dunn ME (2012) Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol 20 (5): 420–429. doi: 10.1037/a0029117
  76. [76]
    Sharma P, Murthy P, Bharath MM (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiat 7 (4): 149–156Google Scholar
  77. [77]
    SIGN (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United KingdomGoogle Scholar
  78. [78]
    Solowij N, Battisti R (2008) The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev 1 (1): 81–98Google Scholar
  79. [79]
    Solowij N, Jones KA, Rozman ME, Davis SM, Ciarrochi J, Heaven PC, Pesa N, Lubman DI, Yucel M (2012) Reflection impulsivity in adolescent cannabis users: a comparison with alcohol-using and non-substance-using adolescents. Psychopharmacology 219 (2): 575–586. doi: 10.1007/s00213-011-2486-y
  80. [80]
    Specht K, Willmes K, Shah NJ, Jäncke L (2003) Assessment of reliability in functional imaging studiesJ MRI 17 (4): 463–471Google Scholar
  81. [81]
    Szutorisz H, Hurd YL (2016) Epigenetic Effects of Cannabis Exposure. Biol Psychiat 79 (7): 586–594. doi: 10.1016/j.biopsych.2015.09.014
  82. [82]
    Thames AD, Arbid N, Sayegh P (2014) Cannabis use and neurocognitive functioning in a non-clinical sample of users. Addict Behav 39 (5): 994–999. doi: 10.1016/j.addbeh.2014.01.019
  83. [83]
    Verdejo-Garcia A, Benbrook A, Funderburk F, David P, Cadet J-L, Bolla KI (2007) The differential relationship between cocaine use and marijuana use on decision-making performance over repeat testing with the Iowa Gambling Task. Drug Alcohol Depend 90 (1): 2–11. doi: 10.1016/j.drugalcdep.2007.02.004
  84. [84]
    Wechsler D (1944) The measurement of adult intelligence. Department of Psychology Princeton University Princeton, New Jersey. Williams and Wilkins, BaltimoreGoogle Scholar
  85. [85]
    Weinstein A, Brickner O, Lerman H, Greemland M, Bloch M, Lester H, Chisin R, Mechoulam R, Bar-Hamburger R, Freedman N, Even-Sapir E (2008) Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology 196 (1): 119–131. doi: 10.1007/s00213-007-0940-7
  86. [86]
    Wong A, Montebello ME, Norberg MM, Rooney K, Lintzeris N, Bruno R, Booth J, Arnold JC, McGregor IS (2013) Exercise increases plasma THC concentrations in regular cannabis users. Drug Alcohol Depend 133 (2): 763–767. doi: 10.1016/j.drugalcdep.2013.07.031
  87. [87]
    Wotjak CT (2005) Role of endogenous cannabinoids in cognition and emotionality. Mini Rev Med Chem 5 (7): 659–670Google Scholar
  88. [88]
    Wrege J, Schmidt A, Walter A, Smieskova R, Bendfeldt K, Radue EW, Lang UE, Borgwardt S (2014) Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Curr Pharmaceut Design 20 (13): 2126–2137Google Scholar
  89. [89]
    Zanettini C, Panlilio LV, Alicki M, Goldberg SR, Haller J, Yasar S (2011) Effects of endocannabinoid system modulation on cognitive and emotional behavior. Front Behav Neurosci 5: 57. doi: 10.3389/fnbeh.2011.00057
  90. [90]
  91. [91]
    Aldington S, Williams M, Nowitz M, Weatherall M, Pritchard A, McNaughton A, Robinson G, Beasley R (2007) Effects of cannabis on pulmonary structure, function and symptoms. Thorax 62 (12): 1058–1063Google Scholar
  92. [92]
    Andreasson S, Allebeck P (1990) Cannabis and mortality among young men: a longitudinal study of Swedish conscripts. Scand J Soc Med 18 (1): 9–15Google Scholar
  93. [93]
    Bab I, Ofek O, Tam J, Rehnelt J, Zimmer A (2008) Endocannabinoids and the regulation of bone metabolism. J Neuroendocrinol 20 (Suppl 1): 69–74Google Scholar
  94. [94]
    Bailey J, Cunny H, Paule M, Slikker WJ (1987) Fetal disposition of delta 9-tetrahydrocannabinol (THC) during late pregnancy in the rhesus monkey. Toxicol Appl Pharmacol 90 (2): 315–321Google Scholar
  95. [95]
    Barber P, Pridmore H, Krishnamurthy V, Roberts S, Spriggs D, Carter KN, Anderson N (2013) Cannabis, ischemic stroke, and transient ischemic attack: a case-control study. Stroke 44 (8): 2327–2329Google Scholar
  96. [96]
    Beaconsfield P, Ginsburg J, Rainsbury R (1972) Marijuana smoking. Cardiovascular effects in man and possible mechanisms. N Engl J Med 287 (5): 209–212Google Scholar
  97. [97]
    Beautrais A, Joyce P, RT M (1999) Cannabis abuse and serious suicide attempts. Addiction 94 (8): 1155–1164Google Scholar
  98. [98]
    Birnbaum B, Pinzone J (2008) Sickle cell trait and priapism: a case report and review of the literature. Cases J 30 (1): 429Google Scholar
  99. [99]
    Biro T, Toth B, Hasko G, Paus R, Pacher P (2009) The endocannabinoid system of the skin in health and disease: novel perspectives and theapeutic opportunities. Trends Pharmacol Sci 30 (8): 411–420Google Scholar
  100. [100]
    Calabria B, Degenhardt L, Hall W, Lynskey M (2010) Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 29 (3): 318–330Google Scholar
  101. [101]
    Callaghan R, Allebeck P, Sidorchuk A (2013) Marijuana use and risk of lung cancer: a 40-year cohort study. Cancer Causes Control 24 (10): 1811–1820Google Scholar
  102. [102]
    Cappelli F, Lazzeri C, Gensini GF, Valente S (2008) Cannabis: a trigger for acute myocardial infarction? A case report. J Cardiovasc Med 9 (7): 725–728Google Scholar
  103. [103]
    Chacko J, Heiner J, Siu W, Macy M, MK T (2006) Association between marijuana use and transitional cell carcinoma. Urology 67 (1): 100–104Google Scholar
  104. [104]
    Charles R, Holt S, Kirkham N (1979) Myocardial infarction and marijuana. Clin Toxicol 14 (4): 433–438Google Scholar
  105. [105]
    Craft RM, Marusich JA, Wiley JL (2013) Sex differences in cannabinoid pharmacology: a reflection of differences in the endocannabinoid system? Life Sci 92 (8–9): 476–481. doi: 10.1016/j.lfs.2012.06.009
  106. [106]
    Daling J, Doody D, Sun X, Trabert BL, Weiss N, Chen S, Biggs M, Starr J, Dey S, Schwartz S (2009) Association of marijuana use and the incidence of testicular germ cell tumors. Cancer 115 (6): 1215–1223Google Scholar
  107. [107]
    Day N, Goldschmidt L, CA T (2006) Prenatal marijuana exposure contributes to the prediction of marijuana use at age 14. Addiction 101 (9): 1313–1322Google Scholar
  108. [108]
    Day N, Leech S, Goldschmidt L (2011) The effects of prenatal marijuana exposure on delinquent behaviours are mediated by measures of neuocognitive functioning. Neurotoxicol Teratol 33 (1): 129–136Google Scholar
  109. [109]
    de Carvalho M, Dourado M, Fernandes I, Araujo C, Mesquita A, Ramos-Jorge M (2015) Head and neck cancer among marijuana users: a meta-analysis of matched case-control studies. Arch Oral Biol 60 (12): 1750–1755Google Scholar
  110. [110]
    Duchene C, Olindo S, Chausson N, Jeannin S, Cohen-Tenoudji P, Smadja D (2010) Cannabis-induced cerebral and myocardial infarction in a young woman. Rev Neurol (Paris) 166 (4): 438–442Google Scholar
  111. [111]
    ElSohly MA, Mehmedic Z, Foster S, Gon C, Chandra S, Church JC (2016) Changes in Cannabis Potency Over the Last 2 Decades (1995–2014): Analysis of Current Data in the United States. Biol Psychiat 79 (7): 613–619. doi: 10.1016/j.biopsych.2016.01.004
  112. [112]
    Esfandyari T, Camilleri M, Busciglio I, Burton D, Baxter K, Zinsmeister A (2007) Effects of a cannabinoid receptor agonist on colonic motor and sensory functions in humans: a randomized, placebo-controlled study. Am J Physiol Gastrointest Liver Physiol 293 (1): G137–145Google Scholar
  113. [113]
    Esse K, Fossati-Bellani M, traylor A, Martin-Schild S (2011) Epidemic of illicit drug use, mechanisms of action/addiction and stroke as a health hazard. Brain Behav 1 (1): 44–54Google Scholar
  114. [114]
    Feng B, Khyatti M, Ben-Ayoub W, Dahmoul S, Ayad M, Maachi F, Bedadra W, Abdoun M, Mesli S, Bakkali H, Jalbout M, Hamdi-Cherif M, Boualga K, Bouaouina N, Chouchane L, Benider A, Ben-Ayed F, Goldgar D, Corbex M (2009) Cannabis, tobacco and domestic fumes intake are associated with nasopharyngeal carcinoma in North Africa. Br J Cancer 101 (7): 1207–1212Google Scholar
  115. [115]
    Fergusson D, Horwood L, Swain-Campbell N (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (9): 1123–1135Google Scholar
  116. [116]
    Forrester M, Merz R (2007) Risk of selected birth defects with prenatal illicit drug use, Hawaii, 1986–2002. J Toxicol Environ Health A 70 (1): 7–18Google Scholar
  117. [117]
    Fredericks A, Benowitz N, Savanapridi C (1981) The cardiovascular and autonomic effect of repeated administration of delta-9-tetrahydrocannabinol to rhesus monkeys. J Pharmacol Exp Ther 216 (2): 247–253Google Scholar
  118. [118]
    Fried P, Watkinson B (2001) Differential effects on faces of attention in adolescents prenatally exposed to cigarettes and marijuana. Neurotoxicol Teratol 23 (5): 421–430Google Scholar
  119. [119]
    Fried P, Watkinson B, Gray R (2003) Differential effects on cognitive functioning in 13- to 16-years-olds prenatally exposed to cigarettes and marihuana. Neurotoxicol Teratol 25 (4): 427–436Google Scholar
  120. [120]
    Gillison M, D’Souza G, Westra W, Sugar E, Xiao W, Begum S, Viscidi R (2008) Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16-negative head and neck cancers. J Natl Cancer Inst 100 (6): 407–420Google Scholar
  121. [121]
    Goyal H, Awad H, Ghali J (2017) Role of cannabis in cardiovascular disorder. J Thorac Dis 9 (7): 2079–2092Google Scholar
  122. [122]
    Greenland S, Richwald G, Honda G (1983) The effects of marijuana use during pregnancy. A study in a low risk home-delivery population. Drug Alcohol Depend 11 (3–4): 359–366Google Scholar
  123. [123]
    Greenland S, Staisch K, Brown N, Gross S (1982) Effects of marijuana on human pregnancy, labor, and delivery. Neurobeh Toxicol Teratol 4 (4): 447–450Google Scholar
  124. [124]
    Grotenhermen F (2010) Cannabis-associated arteritis. Vasa 39 (1): 43–53Google Scholar
  125. [125]
    Gunn J, Rosales C, Center K, Nunez A, Gibson S, Christ C, Ehiri J (2016) Prenatal exposure to cannabis and maternal and child health outcomes: a systematic review and meta-analysis. Br Med J Open 6 (4): e009986Google Scholar
  126. [126]
    Gurney J, Shaw C, Stanley J, Signal V, Sarfati D (2015) Cannabis exposure and risk of testicular cancer: a systematic review and meta-analysis. BMC Cancer 15 (897)Google Scholar
  127. [127]
    Hackam D (2015) Cannabis and stroke: systematic appraisal of case reports. Stroke 46 (3): 852–856Google Scholar
  128. [128]
    Hart S, Fischer OM, Ullrich A (2004) Cannabinoids induce cancer cell proliferation via tumor cecrosis factor alpha-converting enzyme (TACE/ADAM17) – mediated transactivation of the epidermal growth factor receptor. Cancer 64 (6): 1943–1950Google Scholar
  129. [129]
    Hartung B, Kauferstein S, Ritz-Timme S, Daldrup T (2014) Sudden unexpected death under acute influence of cannabis. Forensic Sci Int 237: e11–13Google Scholar
  130. [130]
    Hashibe M, Morgenstern H, Cui Y, Tashkin D, Zhang Z, Cozen W, Mack T, Greenland S (2006) Marijuana use and the risk of lung and upper aerodigestive tract cancers: resulsts of a population-based case-control study. Cancer Epidemiol Biomarkers 15 (10): 1829–1834Google Scholar
  131. [131]
    Hoch E, Bonnet U, Thomasius R, Ganzer F, Havemann-Reinecke U, UW P (2015) Risks associated with the non-medicinal use of cannabis. Dtsch Ärztebl Int 112 (16): 271–278Google Scholar
  132. [132]
    Hu SS, Mackie K (2015) Distribution of the Endocannabinoid System in the Central Nervous System. Handb Exp Pharmacol 231: 59–93. doi: 10.1007/978-3-319-20825-1_3
  133. [133]
    Huang Y, Zhang Z, Tashkin D, Feng B, Straif K, Hashibe M (2015) An epidemiological review of marijuana and cancer: an update. Cancer Epidemiol Biomarkers 24 (1): 15–31Google Scholar
  134. [134]
    Irner T (2012) Substance exposure in utero and developmental consequences in adolescence. Child Neuropsychol 18 (6): 521–549Google Scholar
  135. [135]
    Jones R (2002) Cardiovascular system effects of marijuana. J Clin Pharmacol 42 (11 Suppl): 58S–63SGoogle Scholar
  136. [136]
    Kanakis C, Jr,, Pouget J, Rosen K (1976) The effects of delta-9-tetrahydrocannabinol (cannabis) on cardiac performance with and without beta blockade. Circulation 53 (4): 703–707Google Scholar
  137. [137]
    Korantzopoulos P, Liu T, Papaioannides D, Li G, Goudevenos J (2008) Atrial fibrillation and marijuana smoking. Int J Clin Pract 62 (2): 308–313Google Scholar
  138. [138]
    Kotsalou I, Beorgoulias P, Karydas I, Fourlis S, Sioka C, Zouboulidis A, Demakopoulos N (2007) A rare case of myocardial infarction and ischemia in a cannabis-addicted patient. Clin Nucl Med 32 (2): 130–131Google Scholar
  139. [139]
    Kreuter M, Nowak D, Ruther T, Hoch E, Thomasius R, Vogelberg C, Brockstedt M, Hellmann A, Gohlke H, Jany B, Loddenkemper R (2016) Cannabis-Position Paper of the German Respiratory Society (DGP). Pneumologie 70 (2): 87–97Google Scholar
  140. [140]
    Kung H, Pearson J, Liu X (2003) Risk factors for male and female suicide decedents ages 15–64 in the United States. Results from the 1993 National Mortality Followback Survey. Soc Psychiatry Psychiatr Epidemiol 38 (8): 419–426Google Scholar
  141. [141]
    Lacson J, Carroll J, Tuazon E, Castelao E, Bernstein L, Cortessis V (2012) Population-based case-control study of recreational drug use and testis cancer risk confirms an association between marijuana use and nonseminoma risk. Cancer 118 (21): 5374–5383Google Scholar
  142. [142]
    Lambrecht G, Malbrain M, Coremans P, Verbist L, Verhaegen H (1995) Acute renal infarction and heavy marijuana smoking. Nephron 70 (4): 494–496Google Scholar
  143. [143]
    Landfield P, Cadwallader L, Vinsant S (1988) Quantitative changes in hippocampal structure following long-term exposure. Brain Res 443 (1–2): 47–62Google Scholar
  144. [144]
    Lee M, Hancox R (2011) Effects of smoking cannabis on lung functions. Expert Rev Respir Med 5 (4): 537–546Google Scholar
  145. [145]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  146. [146]
    Liang C, McClean M, Marsit C, Christensen B, Peters E, Nelson H, Kelsey K (2009) A population-based case-control study of marijuana use and head and neck squamous cell carcinoma. Cancer Prevent Res (Phila) 2 (8): 759–768Google Scholar
  147. [147]
    Lorenzetti V, Lubman D, Whittle S, Solowij N, Yucel M (2010) Structural MRI findings in long-term cannabis users: what do we know? Substance Use Misuse 45 (11): 1787–1808Google Scholar
  148. [148]
    Lorenzetti V, Solowij N, Yucel M (2016) The Role of Cannabinoids in Neuroanatomic Alterations in Cannabis Users. Biol Psychiat 79 (7): e17–31. doi: 10.1016/j.biopsych.2015.11.013
  149. [149]
    Lu H-C, Mackie K (2016) An introduction to the endogenous cannabinoid system. Biol Psychiat 79 (7): 516–525Google Scholar
  150. [150]
    Maccarrone M, Bab I, Biro T, Cabral GA, Dey SK, Di Marzo V, Konje JC, Kunos G, Mechoulam R, Pacher P, Sharkey KA, Zimmer A (2015) Endocannabinoid signaling at the periphery: 50 years after THC. Trends Pharmacol Sci 36 (5): 277–296. doi: 10.1016/j.tips.2015.02.008
  151. [151]
    Maccarrone M, Guzman M, Mackie K, Doherty P, Harkany T (2014) Programming of neural cells by (endo)cannabinoids: from physiological rules to emerging therapies. Nat Rev Neurosci 15 (12): 786–801. doi: 10.1038/nrn3846
  152. [152]
    Marks M, Chaturvedi A, Kelsey K, Straif K, Berthiller J, Schwartz S, Smith E, Wyss A, Brennan P, Olshan A, Wei Q, Sturgis E, Zhang Z-F, Morgenstern H, Muscat J, Lazarus P, McClean M, Chen C, Vaughan T, Wunsch-Filho V, Curado M, Koifman S, Mathos E, Menez A, Daudt A, Fernandez L, Posner M, Boffetta P, Lee Y, Hashibe M, D’Souza G (2014) Association of marijuana smoking with oropharyngeal and oral tongue cancers: pooled analysis from the INHANCE consortium. cancer Epidemiol Biomarkers Prevent 23 (1): 160–171Google Scholar
  153. [153]
    Martinez-Martinez E, Martin-Ruiz A, Martin P, Calvo V, Provencio M, Garcia J (2016) CB2 cannabinoid receptor activation promotes colon cancer progression via AKT/GSK3beta signaling pathway. Oncotarget 7 (42): 68781–68791Google Scholar
  154. [154]
    McQueeny T, Padula C, Price J, Medinak K, Logan P, Tapert S (2011) Gender effects on amygdala morphometry in adolescent marijuana users. Behav Brain Res 224 (1): 128–134Google Scholar
  155. [155]
    Mehra R, Moore B, Crothers K, Tetrault J, Fiellin D (2006) The association between marijuana smoking and lung cancer: a systematic review. Arch Intern Med 166 (13): 1359–1367Google Scholar
  156. [156]
    Montisci M, Thiene G, Ferrara S, Basso C (2008) Cannabis and cocaine: a lethal cocktail triggering coronary sudden death. Cardiovasc Pathol 17 (5): 344–346Google Scholar
  157. [157]
    Moretti S, Franchi S, Castelli M, Amodeo G, Somaini L, Panerai A, Scacerdote P (2015) Exposure of Adolescent Mice to Delta-9-Tetrahydrocannabinol Induces Long-Lasting Modulation of Pro- and Anti-Inflammatory Cytokines in Hypothalamus and Hippycampus Similar to that Observed for Peripheral Macrophages. J Neuroimmune Pharmacol 10 (2): 371–379Google Scholar
  158. [158]
    Mukamal K, Maclure M, Muller J, Mittleman M (2008) An exploratory prospective study of marijuana use and mortality following acute myodardial infarction. Am Heart J 155 (3): 465–470Google Scholar
  159. [159]
    O’Sullivan S, Tarling E, Bennett A, Kendall D, Randall M (2005) Novel time-dependent vascular actions of Delta9-tetrahydrocannabino mediated by peroxisome proliferator-activated receptor gamma. Biochem Biophys Res Commun 337 (3): 824–831Google Scholar
  160. [160]
    OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford
  161. [161]
    Perez-Lopez F, Larrad-Mur L, Kallen A, Chedraui P, Taylor H (2010) Gender differences in cardiovascular disease: hormonal and biochemical influences. Reprod Sci 17 (6): 511–531Google Scholar
  162. [162]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengerichGoogle Scholar
  163. [163]
    Pisanti S, Picardi P, D’Alessandro A, Laezza C, Bifulco M (2013) The endocannabinoid signaling system in cancer. Trends Pharmacol Sci 34 (5): 273–282Google Scholar
  164. [164]
    Plange N, Arend K, Kaup M, Doehmen B, Adams H, Hendricks S, Cordes A, Huth J, Sponsel W, Remky A (2007) Dronabinol and retinal hemodynamics in humans. Am J Ophthalmol 143 (1): 173–174Google Scholar
  165. [165]
    Reece A (2009) Chronic toxicology of cannabis. Clin Toxicol (Philadelphia, Pa) 47 (6): 517–524Google Scholar
  166. [166]
    Rocchetti M, Crescini A, Borgwardt S, Caverzasi E, Politi P, Atakan Z, Fusar-Poli P (2013) Is cannabis neurotoxic for the healthy brain? A meta-analytical review of structural brain alterations in non-psychotic users. Psachiat Clin Neurosci 67 (7): 483–492Google Scholar
  167. [167]
    Scallet A, Uemura E, Andrews A, Ali S, McMillan D, Paule M, Brown RM, Slikker W, Jr., (1987) Morphometric studies of the rat hippocampus following chronic delta-9-tetrahydrocannabinol (THC). Brain Res 436 (1): 193–198Google Scholar
  168. [168]
    Schneider M (2008) Puberty as a highly vulnerable developmental period for the consequences of cannabis exposure. Addict Biol 13 (2): 253–263Google Scholar
  169. [169]
    Schneider M, Kasanetz F, Lynch D, Friemel C, Hurst D, Steindel F, Monory K, Schafer C, Miederer I, Leweke F, Schreckenberger M, Lutz B, Reggio P, Manzoni OJ, Spanagel R (2015) Enhanced Functional Activity of the Cannabinoid Type-1 Receptor Mediates Adolescent Behavior. J Neurosci 35 (41): 13975–13988Google Scholar
  170. [170]
    Sidney S (2002) Cardiovascular consequences of marijuana use. J Clin Pharmacol 42 (11 Suppl): 64S–70SGoogle Scholar
  171. [171]
    Sidney S, Beck J, Tekawa I, Quesenberry C, Friedman G (1997a) Marijuana use and mortality. Am J Public Health 87 (4): 585–590Google Scholar
  172. [172]
    Sidney S, Quesenberry C, Friedman G, Tekawa I (1997b) Marijuana use and cancer incidence (California, United States). Cancer Causes Control 8 (5): 722–728Google Scholar
  173. [173]
    SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology Checklist. Edinburgh, United KingdomGoogle Scholar
  174. [174]
    Sridhar K, Raub W, Metsch L, Surrat HL, Inciardi J, Duncan R, Anwyl R, McCoy C (1994) Possible role of marijuana smoking as a carcinogen in the development of lung cancer at a young age. J Psychoact Drugs 26 (3): 285–288Google Scholar
  175. [175]
    Stanley C, Hind W, Tufarelli C, O’Sullivan S (2016) The endocannabinoid anandamide causes endothelium-dependent vasorelaxation in human mesenteric arteries. Pharmacol Res 113 (Pt A): 356–363Google Scholar
  176. [176]
    Sterne J, Ducastaing C (1960) Arteritis caused by Cannabis indica. Arch Mal Coeur Vaiss Feb (53): 143–147Google Scholar
  177. [177]
    Storr M, Devlin S, Kaplan G, Panaccione R, Andrews C (2014) Cannabis use provides symptom relief in patients with inflammatory bowel disease but is associated with worse disease prognosis in patients with Crohn’s disease. Inflammatory bowel diseases 20 (3): 472–480Google Scholar
  178. [178]
    Swift W, Wong A, Arnold J, MdGregor I (2013) Analysis of cannabis seizures in NSW, Australia: cannabis potency and cannabinoid profile. PloS one 8 (7): e70052. doi: 10.1371/journal.pone.0070052. Print 2013
  179. [179]
    Tan C, Hatam N, Treasure T (2006) Bullous disease of the lung and cannabis smoking: insufficient evidence for a causative link. J R Soc Med 99 (2): 77–80Google Scholar
  180. [180]
    Tashkin D, Shapiro B, Frank I (1976) Acute effects of marihuana on airway dynamics in spontaneous and experimentally produced bronchial asthma. In: McBraude, Szara S (eds) The pharmacology of Marihuana. Raven Press, New YorkGoogle Scholar
  181. [181]
    Taylor F, 3rd (1988) Marijuana as a potential respiratory tract carcinogen: a retrospective analysis of a community hospital population. South Med J 81 (10): 1213–1216Google Scholar
  182. [182]
    Tetrault J, Crothers K, Moore B, Mehra R, Concato J, Fiellin D (2007) Effects of marijuana smoking on pulmonary function and respiratory complications: a systematic review. Arch Intern Med 167 (3): 221–228Google Scholar
  183. [183]
    Ting J (2007) Reversible cardiomyopathy associated with acute inhaled marijuana use in a young adult. Clin Toxicol (Philadelphia, Pa) 45 (4): 432–434Google Scholar
  184. [184]
    Trabert B, Sigurdson A, Sweeney A, Strom S, McGlynn K (2011) Marijuana use and testicular germ cell tumors. Cancer 117 (4): 848–853Google Scholar
  185. [185]
    van Gelder M, Reefhuis J, Caton A, Werler M, Druschel C, Roeleveld N (2009) Maternal periconceptional illicit drug use and the risk of congenital malformations. Epidemiology 20 (1): 60–66Google Scholar
  186. [186]
    van Skike C, Maggio S, Reynolds A, Casey E, Bardo M, Dwoskin L, Prendergast M, Nixon K (2016) Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse. Prog Neuropsychopharmacol Biol Psychiat 65: 269–287Google Scholar
  187. [187]
    Vassalle C, Simoncini T, Chedraui P, Perez-Lopez F (2012) Why sex matters: the biological mechanisms of cardiovascular disease. Gynecol Endocrinol 28 (9): 746–751Google Scholar
  188. [188]
    Weinsheimer R, Yanchar N (2008) Impact of maternal substance abuse and smoking on children with gastroschisis. J Pediatr Surg 43 (5): 879–883Google Scholar
  189. [189]
    Westover A, McBride S, Haley R (2007) Stroke in young adults who abuse amphetamines or cocaine: a population-based study of hospitalized patients. Arch Gen Psychiat 64 (4): 495–502Google Scholar
  190. [190]
    Wilcox H, Anthony J (2004) The development of suicide ideation and attempts: an epidemiologic study of first graders followed into young adulthood. Drug Alcohol Depend Dec 7 (76 Suppl): S53–67Google Scholar
  191. [191]
    Williams J, Ross L (2007) Consequence of prenatal toxin exposure for mental health in children and adolescents: a systematic review. Eur Child Adolesc Psychiat 16 (4): 243–253Google Scholar
  192. [192]
    Zhang L, Morgenstern H, Greenland S, Chang S, Lazarus P, Teare M, Woll P, Orlow I, Cox B, Brhane Y, Liu G, Hung R (2015) Cannabis smoking and lung cancer risk: Pooled analysis in the International Lung Cancer Consortium. Int J Cancer 36 (4): 894–903Google Scholar
  193. [193]
    Zhang Z, Morgenstern H, Spitz M, Tashkin D, Yu G, Marshall J, Hsu T, Schantz S (1999) Marijuana use and increased risk of squamous cell carcinoma of the head and neck. Cancer Epidemiol Biomarkers 8 (12): 1071–1078Google Scholar
  194. [194]
    Aloise-Young PA, Chavez EL (2002) Not all school dropouts are the same: Ethnic differences in the relation between reason for leaving school and adolescent substance use. Psychol Schools 39 (5): 539–547Google Scholar
  195. [195]
    Amsterdam Jv, Nutt D, Phillips L, Brink Wvd (2015) European rating of drug harms. J Psychopharmacol 29 (6): 655–660. doi: 10.1177/0269881115581980
  196. [196]
    Andréasson S, Allebeck P, Engström A, Rydberg U (1987) Cannabis and schizophrenia. A longitudinal study of Swedish conscripts. Lancet 2: 1483Google Scholar
  197. [197]
    Arseneault L, Cannon M, Poulton R, Murray R, Caspi A, Moffitt TE (2002) Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. Br Med J 325 (7374): 1212–1213Google Scholar
  198. [198]
    Arseneault L, Moffitt TE, Caspi A, Taylor PJ, Silva PA (2000) Mental disorders and violence in a total birth cohort: results from the Dunedin Study. Arch Gen Psychiat 57 (10): 979–986Google Scholar
  199. [199]
    Beauvais F, Chavez EL, Oetting ER, Deffenbacher JL, Cornell GR (1996) Drug use, violence, and victimization among White American, Mexican American, and American Indian dropouts, students with academic problems, and students in good academic standing. J Counsel Psychol 43 (3): 292Google Scholar
  200. [200]
    Bray JW, Zarkin GA, Ringwalt C, Qi J (2000) The relationship between marijuana initiation and dropping out of high school. Health Econom 9 (1): 9–18Google Scholar
  201. [201]
    Brook JS, Balka EB, Whiteman M (1999a) The risks for late adolescence of early adolescent marijuana use. Am J Public Health 89 (10): 1549–1554Google Scholar
  202. [202]
    Brook JS, Cohen P, Brook DW (1998) Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiat 37 (3): 322–330. doi: 10.1097/00004583-199803000-00018
  203. [203]
    Brook JS, Lee JY, Finch SJ, Koppel J, Brook DW (2011) Psychosocial factors related to cannabis use disorders. Subst Abuse 32 (4): 242–251Google Scholar
  204. [204]
    Brook JS, Richter L, Whiteman M, Cohen P (1999b) Consequences of adolescent marijuana use: incompatibility with the assumption of adult roles. Genet Social Gen Psychol Monogr 125 (2): 193–207Google Scholar
  205. [205]
    Brook JS, Whiteman M, Finch SJ, Cohen P (1996) Young adult drug use and delinquency: childhood antecedents and adolescent mediators. J Am Acad Child Adolesc Psychiat 35 (12): 1584–1592. doi: 10.1097/00004583-199612000-00009
  206. [206]
    Cavazos-Rehg PA, Krauss MJ, Spitznagel EL, Schootman M, Cottler LB, Bierut LJ (2011) Number of sexual partners and associations with initiation and intensity of substance use. AIDS Behav 15 (4): 869–874Google Scholar
  207. [207]
    Coffey C, Patton GC (2016) Cannabis Use in Adolescence and Young Adulthood: A Review of Findings from the Victorian Adolescent Health Cohort Study. Can J Psychiat 61 (6): 318–327. doi: 10.1177/0706743716645289
  208. [208]
    de Oliveira AM, Buchain PC, Vizzotto ADB, Elkis H, Cordeiro Q (2013) Psychosocial Impact. In: Gellman MD, Turner JR (eds) Encyclopedia of Behavioral Medicine. Springer New York, pp 1583–1584. doi: 10.1007/978-1-4419-1005-9_919
  209. [209]
    Dornbusch SM, Lin IC, Munroe PT, Bianchi AJ (1999) Adolescent polydrug use and violence in the United States. International journal of adolescent medicine and health 11 (3–4): 197–220. doi: 10.1515/ijamh.1999.11.3-4.197
  210. [210]
    Edelman NL, de Visser RO, Mercer CH, McCabe L, Cassell JA (2015) Targeting sexual health services in primary care: A systematic review of the psychosocial correlates of adverse sexual health outcomes reported in probability surveys of women of reproductive age. Prevent Med 81: 345–356. doi: http://dx.doi.org/10.1016/j.ypmed.2015.09.019
  211. [211]
    Eggert LL, Herting JR (1993) Drug involvement among potential dropouts and „typical” youth. J Drug Educn 23 (1): 31–55Google Scholar
  212. [212]
    Ellickson P, Bui K, Bell R, McGuigan KA (1998) Does early drug use increase the risk of dropping out of high school? J Drug Issue 28 (2): 357–380Google Scholar
  213. [213]
    Ellickson PL, McGuigan KA (2000) Early predictors of adolescent violence. Am J Public Health 90 (4): 566–572Google Scholar
  214. [214]
    Ensminger ME, Lamkin RP, Jacobson N (1996) School leaving: a longitudinal perspective including neighborhood effects. Child Dev 67 (5): 2400–2416Google Scholar
  215. [215]
    Fergusson DM, Boden JM (2008) Cannabis use and later life outcomes. Addiction 103 (6): 969–976; discussion 977–968. doi: 10.1111/j.1360-0443.2008.02221.x
  216. [216]
    Fergusson DM, Boden JM, Horwood LJ (2015) Psychosocial sequelae of cannabis use and implications for policy: findings from the Christchurch Health and Development Study. Social p§sychiat Psychiat Epidemiol 50 (9): 1317–1326Google Scholar
  217. [217]
    Fergusson DM, Horwood LJ (1997) Early onset cannabis use and psychosocial adjustment in young adults. Addiction 92 (3): 279–296Google Scholar
  218. [218]
    Fergusson DM, Horwood LJ (2000) Does cannabis use encourage other forms of illicit drug use? Addiction 95 (4): 505–520Google Scholar
  219. [219]
    Fergusson DM, Horwood LJ (2001) The Christchurch Health and Development Study: review of findings on child and adolescent mental health. Aust NZ J Psychiat 35 (3): 287–296Google Scholar
  220. [220]
    Fergusson DM, Horwood LJ, Beautrais AL (2003a) Cannabis and educational achievement. Addiction 98 (12): 1681–1692Google Scholar
  221. [221]
    Fergusson DM, Horwood LJ, Swain-Campbell N (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97 (9): 1123–1135Google Scholar
  222. [222]
    Fergusson DM, Horwood LJ, Swain-Campbell NR (2003b) Cannabis dependence and psychotic symptoms in young people. Psychol Med 33 (1): 15–21Google Scholar
  223. [223]
    Fergusson DM, Lynskey MT, Horwood LJ (1996) The short-term consequences of early onset cannabis use. J Abnorm Child Psychol 24 (4): 499–512Google Scholar
  224. [224]
    Flisher AJ, Chalton DO (1995) High-school dropouts in a working-class South African community: selected characteristics and risk-taking behaviour. J Adolesc 18 (1): 105Google Scholar
  225. [225]
    Friedman AS, Glassman K, Terras BA (2001) Violent behavior as related to use of marijuana and other drugs. J Addict Dis 20 (1): 49–72. doi: 10.1300/J069v20n01_06
  226. [226]
    Friedman AS, Kramer S, Kreisher C, Granick S (1996) The relationships of substance abuse to illegal and violent behavior, in a community sample of young adult African American men and women (gender differences). J Subst Abuse 8: 379–402Google Scholar
  227. [227]
    Gfroerer JC, Greenblatt JC, Wright DA (1997) Substance use in the US college-age population: differences according to educational status and living arrangement. Am J Public Health 87 (1): 62–65Google Scholar
  228. [228]
    Green KM, Ensminger ME (2006) Adult social behavioral effects of heavy adolescent marijuana use among African Americans. Dev Psychol 42 (6): 1168–1178. doi: 10.1037/0012-1649.42.6.1168
  229. [229]
    Horwood LJ, Fergusson DM, Hayatbakhsh MR, Najman JM, Coffey C, Patton GC, Silins E, Hutchinson DM (2010) Cannabis use and educational achievement: findings from three Australasian cohort studies. Drug Alcohol Depend 110 (3): 247–253. doi: http://dx.doi.org/10.1016/j.drugalcdep.2010.03.008
  230. [230]
    International Narcotics Control Board (2013) Comments on the reported statistics on psychotropic substance for 2012. ViennaGoogle Scholar
  231. [231]
    Kaestner R (1994) New Estimates of the Effect of Marijuana and Cocaine Use on Wages. Indust Labor Relat Rev 47 (3): 454–470. doi: 10.2307/2524977
  232. [232]
    Kandel D (1975) Stages in adolescent involvement in drug use. Science 190 (4217): 912–914Google Scholar
  233. [233]
    Kandel D, Chen K, Gill A (1995) The Impact of Drug Use on Earnings: A Life-Span Perspective. Social Forces 74 (1): 243–270. doi: 10.2307/2580631
  234. [234]
    Kandel DB, Yamaguchi K, Chen K (1992) Stages of progression in drug involvement from adolescence to adulthood: further evidence for the gateway theory. J Stud Alcohol 53 (5): 447–457Google Scholar
  235. [235]
    Kogan SM, Luo Z, Brody GH, Murry VM (2005) The influence of high school dropout on substance use among African American youth. J Ethnic Substance Abuse 4 (1): 35–51Google Scholar
  236. [236]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  237. [237]
    Lynskey MT, Coffey C, Degenhardt L, Carlin JB, Patton G (2003) A longitudinal study of the effects of adolescent cannabis use on high school completion. Addiction 98 (5): 685–692Google Scholar
  238. [238]
    Macleod J, Copello A, Crome I, Smith GD, Egger M, Hickman M, Judd A, Oakes R, Oppenkowski T, Stokes-Lampard H (2005) The psychosocial consequences of drug misuse: A systematic review of longitudinal studies. Drugs Educ Prevent Policy 12 (Suppl 1): 85–89Google Scholar
  239. [239]
    Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith GD (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363 (9421): 1579–1588. doi: 10.1016/S0140-6736(04)16200-4
  240. [240]
    McGee R, Williams S, Poulton R, Moffitt T (2000) A longitudinal study of cannabis use and mental health from adolescence to early adulthood. Addiction 95 (4): 491–503Google Scholar
  241. [241]
    Najman JM, Bor W, O’Callaghan M, Williams GM, Aird R, Shuttlewood G (2005) Cohort profile: the Mater-University of Queensland study of pregnancy (MUSP). Int J Epidemiol 34 (5): 992–997Google Scholar
  242. [242]
    National Academies of Sciences E, and Medicine. (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. National Academies Press., Washington, DC. doi: 10.17226/24625.
  243. [243]
    Newcomb MD, Bentler PM (1988) Consequences of adolescent drug use: Impact on the lives of young adults. Sage Publications, Thousand Oaks, CalGoogle Scholar
  244. [244]
    Newcomb MD, Maddahian E, Skager R, Bentler PM (1987) Substance abuse and psychosocial risk factors among teenagers: Associations with sex, age, ethnicity, and type of school. Am J Drug Alcohol Abuse 13 (4): 413–433Google Scholar
  245. [245]
    OCEBM (2011) The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine, 2 edn. http://www.cebm.net/index.aspx?o = 5653,
  246. [246]
    Patton GC, Coffey C, Carlin JB, Degenhardt L, Lynskey M, Hall W (2002) Cannabis use and mental health in young people: cohort study. Br Med J 325 (7374): 1195–1198Google Scholar
  247. [247]
    Patton GC, Harris R, Carlin JB, Hibbert ME, Coffey C, Schwartz M, Bowes G (1997) Adolescent suicidal behaviours: a population-based study of risk. Psychol Med 27 (3): 715–724Google Scholar
  248. [248]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengerichGoogle Scholar
  249. [249]
    Roebuck MC, French MT, Dennis ML (2004) Adolescent marijuana use and school attendance. Econom Educ Rev 23 (2): 133–141Google Scholar
  250. [250]
    Scheier LM, Botvin GJ (1995) Effects of early adolescent drug use on cognitive efficacy in early-late adolescence: a developmental structural model. J Subst Abuse 7 (4): 379–404Google Scholar
  251. [251]
    Schlossarek S, Kempkensteffen J, Reimer J, Verthein U (2016) Psychosocial Determinants of Cannabis Dependence: A Systematic Review of the Literature. Eur Addict Res 22 (3): 131–144Google Scholar
  252. [252]
    SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology checklist. Edinburgh, United KingdomGoogle Scholar
  253. [253]
    Stenbacka M, Allebeck P, Brandt L, Romelsjo A (1992) Intravenous drug abuse in young men: risk factors assessed in a longitudinal perspective. Scand J Soc Med 20 (2): 94–101Google Scholar
  254. [254]
    Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction 103 (8): 1361–1370Google Scholar
  255. [255]
    Townsend L, Flisher AJ, King G (2007) A systematic review of the relationship between high school dropout and substance use. Clin Child Family Psychol Rev 10 (4): 295–372. doi: 10.1007/s10567-007-0023-7
  256. [256]
    Van den Bree MB, Pickworth WB (2005) Risk factors predicting changes in marijuana involvement in teenagers. Arch Gen Psychiat 62 (3): 311–319Google Scholar
  257. [257]
    White HR, Loeber R, Stouthamer-Loeber M, Farrington DP (1999) Developmental associations between substance use and violence. Dev Pychopathol 11 (4): 785–803Google Scholar
  258. [258]
    Windle M (1997) Mate similarity, heavy substance use and family history of problem drinking among young adult women. J Stud Alcohol 58 (6): 573–580Google Scholar
  259. [259]
    Zimmerman MA, Maton KI (1992) Life-style and substance use among male African American urban adolescents: A cluster analytic approach. Am J Community Psychol 20 (1): 121–138Google Scholar
  260. [260]
    Anderson BM, Rizzo M, Block RI, Pearlson GD, O’Leary DS (2010) Sex differences in the effects of marijuana on simulated driving performance. J Psychoact Drugs 42 (1): 19–30. doi: 10.1080/02791072.2010.10399782
  261. [261]
    Asbridge M, Hayden JA, Cartwright JL (2012) Acute cannabis consumption and motor vehicle collision risk: systematic review of observational studies and meta-analysis. Br Med J 344: e536. doi: 10.1136/bmj.e536
  262. [262]
    Asbridge M, Poulin C, Donato A (2005) Motor vehicle collision risk and driving under the influence of cannabis: evidence from adolescents in Atlantic Canada. Accid Anal Prevent 37 (6): 1025–1034. doi: 10.1016/j.aap.2005.05.006
  263. [263]
    Baldock M (2007) Review of the literature on cannabis and crash risk. Centre for Automotive Safety Research, University of Adelade, AustraliaGoogle Scholar
  264. [264]
    Blows S, Ivers RQ, Connor J, Ameratunga S, Woodward M, Norton R (2005) Marijuana use and car crash injury. Addiction 100 (5): 605–611. doi: 10.1111/j.1360-0443.2005.01100.x
  265. [265]
    Brault M, Dussault, C, Bouchard, J, Lemire, AM (2004) The contribution of alcohol and other drugs among fatally injured drivers in Quebec: final results. Paper presented at the 17th International Conference on Alcohol, Drugs and Traffic Safety Glasgow, United Kingdom, August 8–13, 2004Google Scholar
  266. [266]
    Chait LD, Perry JL (1994) Acute and residual effects of alcohol and marijuana, alone and in combination, on mood and performance. Psychopharmacology 115 (3): 340–349Google Scholar
  267. [267]
    Drummer O (1995) A review of the contribution of drugs in drivers to road accidents. Government Printer, MelbourneGoogle Scholar
  268. [268]
    Drummer OH, Gerostamoulos J, Batziris H, Chu M, Caplehorn J, Robertson MD, Swann P (2004) The involvement of drugs in drivers of motor vehicles killed in Australian road traffic crashes. Accid Anal Prevent 36 (2): 239–248Google Scholar
  269. [269]
    Elvik R (2013) Risk of road accident associated with the use of drugs: A systematic review and meta-analysis of evidence from epidemiological studies. Accident Anal Prevent 60: 254–267. doi: 10.1016/j.aap.2012.06.017
  270. [270]
    EMCDDA (2014) Drug use, impaired driving and traffic accidents. Insights, 2nd edn. LisbonGoogle Scholar
  271. [271]
    Fergusson DM, Horwood LJ (2001) Cannabis use and traffic accidents in a birth cohort of young adults. Accid Anal Prevent 33 (6): 703–711Google Scholar
  272. [272]
    Girotto E, Mesas AE, de Andrade SM, Birolim MM (2014) Psychoactive substance use by truck drivers: a systematic review. Occupat Environ Med 71 (1): 71–76. doi: 10.1136/oemed-2013-101452
  273. [273]
    Hartman RL, Huestis MA (2013) Cannabis effects on driving skills. Clin Chem 59 (3): 478–492. doi: 10.1373/clinchem.2012.194381
  274. [274]
    Lamers CT, Ramaekers JG (2001) Visual search and urban driving under the influence of marijuana and alcohol. Human Psychopharmacol 16 (5): 393–401. doi: 10.1002/hup.307
  275. [275]
    Laumon B, Gadegbeku B, Martin JL, Biecheler MB, Group SAM (2005) Cannabis intoxication and fatal road crashes in France: population based case-control study. Br Med J 331 (7529): 1371. doi: 10.1136/bmj.38648.617986.1F
  276. [276]
    Lenne MG, Dietze PM, Triggs TJ, Walmsley S, Murphy B, Redman JR (2010) The effects of cannabis and alcohol on simulated arterial driving: Influences of driving experience and task demand. Accid Anal Prevent 42 (3): 859–866. doi: 10.1016/j.aap.2009.04.021
  277. [277]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  278. [278]
    Li M-C, Brady JE, DiMaggio CJ, Lusardi AR, Tzong KY, Li G (2012) Marijuana use and motor vehicle crashes. Epidemiol Rev 34 (1): 65–72Google Scholar
  279. [279]
    Liguori A, Gatto CP, Jarrett DB (2002) Separate and combined effects of marijuana and alcohol on mood, equilibrium and simulated driving. Psychopharmacology 163 (3–4): 399–405. doi: 10.1007/s00213-002-1124-0
  280. [280]
    Liguori A, Gatto CP, Robinson JH (1998) Effects of marijuana on equilibrium, psychomotor performance, and simulated driving. Behav Pharmacol 9 (7): 599–609Google Scholar
  281. [281]
    Longo MC, Hunter CE, Lokan RJ, White JM, White MA (2000) The prevalence of alcohol, cannabinoids, benzodiazepines and stimulants amongst injured drivers and their role in driver culpability: part ii: the relationship between drug prevalence and drug concentration, and driver culpability. Accident Anal Prevent 32 (5): 623–632Google Scholar
  282. [282]
    McCabe SE, Cranford JA, Morales M, Young A (2006) Simultaneous and concurrent polydrug use of alcohol and prescription drugs: prevalence, correlates, and consequences. J Stud Alcohol 67 (4): 529–537Google Scholar
  283. [283]
    McDonald J, Schleifer L, Richards JB, de Wit H (2003) Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology 28 (7): 1356–1365. doi: 10.1038/sj.npp.1300176
  284. [284]
    Menetrey A, Augsburger M, Favrat B, Pin MA, Rothuizen LE, Appenzeller M, Buclin T, Mangin P, Giroud C (2005) Assessment of driving capability through the use of clinical and psychomotor tests in relation to blood cannabinoids levels following oral administration of 20 mg dronabinol or of a cannabis decoction made with 20 or 60 mg Delta9-THC. J Anal Toxicol 29 (5): 327–338Google Scholar
  285. [285]
    Mura P, Kintz P, Ludes B, Gaulier JM, Marquet P, Martin-Dupont S, Vincent F, Kaddour A, Goulle JP, Nouveau J, Moulsma M, Tilhet-Coartet S, Pourrat O (2003) Comparison of the prevalence of alcohol, cannabis and other drugs between 900 injured drivers and 900 control subjects: results of a French collaborative study. Forensic Sci Int 133 (1–2): 79–85Google Scholar
  286. [286]
    Musshoff F, Madea B (2006) Review of biologic matrices (urine, blood, hair) as indicators of recent or ongoing cannabis use. Ther Drug Monitoring 28 (2): 155–163. doi: 10.1097/01.ftd.0000197091.07807.22
  287. [287]
    OCEBM (2011) Levels of Evidence Working Group, The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford
  288. [288]
    Papafotiou K, Carter JD, Stough C (2005) The relationship between performance on the standardised field sobriety tests, driving performance and the level of Delta9-tetrahydrocannabinol (THC) in blood. Forensic Sci Int 155 (2–3): 172–178. doi: 10.1016/j.forsciint.2004.11.009
  289. [289]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch: eine Expertise zu gesundheitlichen und psychosozialen Folgen; ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publ., LengerichGoogle Scholar
  290. [290]
    Peterson J, Welch V, Losos M, Tugwell P (2011) The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. [http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp]
  291. [291]
    Rafaelsen OJ, Bech P, Christiansen J, Christrup H, Nyboe J, Rafaelsen L (1973a) Cannabis and alcohol: effects on stimulated car driving. Science 179 (4076): 920–923Google Scholar
  292. [292]
    Rafaelsen OJ, Bech P, Rafaelsen L (1973b) Simulated car driving influenced by cannabis and alcohol. Pharmakopsychiatr Neuropsychopharmakol 6 (2): 71–83. doi: 10.1055/s-0028-1094370
  293. [293]
    Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31 (10): 2296–2303. doi: 10.1038/sj.npp.1301068
  294. [294]
    Ramaekers JG, Robbe HW, O’Hanlon JF (2000) Marijuana, alcohol and actual driving performance. Human Psychopharmacol 15 (7): 551–558. doi: 10.1002/1099-1077(200010)15:7<551:AID-HUP236>3.0.CO;2-P
  295. [295]
    Robbe H (1998) Marijuana’s impairing effects on driving are moderate when taken alone but severe when combined with alcohol. Human Psychopharmacol Clin Exp 13 (S2): S70-S78Google Scholar
  296. [296]
    Robbe H, O’Hanlon, JF (1999) Marijuana, alcohol and actual driving performance. Washington, DCGoogle Scholar
  297. [297]
    Ronen A, Chassidim HS, Gershon P, Parmet Y, Rabinovich A, Bar-Hamburger R, Cassuto Y, Shinar D (2010) The effect of alcohol, THC and their combination on perceived effects, willingness to drive and performance of driving and non-driving tasks. Accid Anal Prevent 42 (6): 1855–1865. doi: 10.1016/j.aap.2010.05.006
  298. [298]
    Ronen A, Gershon P, Drobiner H, Rabinovich A, Bar-Hamburger R, Mechoulam R, Cassuto Y, Shinar D (2008) Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prevent 40 (3): 926–934. doi: 10.1016/j.aap.2007.10.011
  299. [299]
    Senna MC, Augsburger M, Aebi B, Briellmann TA, Donze N, Dubugnon JL, Iten PX, Staub C, Sturm W, Sutter K (2010) First nationwide study on driving under the influence of drugs in Switzerland. Forensic Sci Int 198 (1–3): 11–16. doi: 10.1016/j.forsciint.2010.02.014
  300. [300]
    Smiley A (1999) Marijuana: on-road and driving simulator studies. In: Kalant H CW, Hall W, Smart RG (ed) The health effects of cannabis. Centre for Addiction and Mental Health, Toronto, pp 173–191Google Scholar
  301. [301]
    Terhune K, Ippolito C, Hendricks D, Michalovic J, Bogema S, Santinga P, Blomberg R, Preusser D (1992) The incidence and role of drugs in fatally injured drivers. Final report. [https://catalog.hathitrust.org/Record/005516221]
  302. [302]
    Walsh JM, Flegel R, Atkins R, Cangianelli LA, Cooper C, Welsh C, Kerns TJ (2005) Drug and alcohol use among drivers admitted to a Level-1 trauma center. Accid Anal Prevent 37 (5): 894–901. doi: 10.1016/j.aap.2005.04.013
  303. [303]
    Walsh JM, Flegel R, Cangianelli LA, Atkins R, Soderstrom CA, Kerns TJ (2004) Epidemiology of alcohol and other drug use among motor vehicle crash victims admitted to a trauma center. Traffic Inj Prevent 5 (3): 254–260. doi: 10.1080/15389580490465319
  304. [304]
    Woratanarat P, Ingsathit A, Suriyawongpaisal P, Rattanasiri S, Chatchaipun P, Wattayakorn K, Anukarahanonta T (2009) Alcohol, illicit and non-illicit psychoactive drug use and road traffic injury in Thailand: a case-control study. Accid Anal Prevent 41 (3): 651–657. doi: 10.1016/j.aap.2009.03.002
  305. [305]
    Abrantes AM, Lee CS, MacPherson L, Strong DR, Borrelli B, Brown RA (2009) Health risk behaviors in relation to making a smoking quit attempt among adolescents. J Behav Med 32 (2): 142–149. doi: 10.1007/s10865-008-9184-1
  306. [306]
    Agrawal A, Lynskey MT (2009) Tobacco and cannabis co-occurrence: does route of administration matter? Drug Alcohol Depend 99 (1–3): 240–247. doi: 10.1016/j.drugalcdep.2008.08.007
  307. [307]
    Agrawal A, Lynskey MT, Kapoor M, Bucholz KK, Edenberg HJ, Schuckit M, Brooks A, Hesselbrock V, Kramer J, Saccone N, Tischfield J, Bierut LJ (2015) Are genetic variants for tobacco smoking associated with cannabis involvement? Drug Alcohol Depend 150: 183–187. doi: 10.1016/j.drugalcdep.2015.02.029
  308. [308]
    Agrawal A, Lynskey MT, Madden PA, Pergadia ML, Bucholz KK, Heath AC (2009) Simultaneous cannabis and tobacco use and cannabis-related outcomes in young women. Drug Alcohol Depend 101 (1–2): 8–12. doi: 10.1016/j.drugalcdep.2008.10.019
  309. [309]
    Agrawal A, Madden PA, Bucholz KK, Heath AC, Lynskey MT (2008a) Transitions to regular smoking and to nicotine dependence in women using cannabis. Drug Alcohol Depend 95 (1–2): 107–114. doi: 10.1016/j.drugalcdep.2007.12.017
  310. [310]
    Agrawal A, Pergadia ML, Lynskey MT (2008b) Is there evidence for symptoms of cannabis withdrawal in the national epidemiologic survey of alcohol and related conditions? Am J Addict 17 (3): 199–208. doi: 10.1080/10550490802019519
  311. [311]
    American Psychiatric Association (2013) Diagnostic and statistical manual of mental disorders: DSM-5. American Psychiatric Association, Arlington, VAGoogle Scholar
  312. [312]
    APA APA (American Psychiatric Association) (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association, Washington, DCGoogle Scholar
  313. [313]
    Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jorgensen P (2007) Psychopathology among cannabis-dependent treatment seekers and association with later substance abuse treatment. J Subst Abuse Treat 32 (2): 113–119. doi: 10.1016/j.jsat.2006.07.005
  314. [314]
    Arseneault L, Cannon M, Witton J, Murray RM (2004) Causal association between cannabis and psychosis: examination of the evidence. Br J Psychiat 184 (2): 110–117Google Scholar
  315. [315]
    Baek JH, Zheng Y, Darlington CL, Smith PF (2008) Cannabinoid CB2 receptor expression in the rat brainstem cochlear and vestibular nuclei. Acta Otolaryngol 128 (9): 961–967. doi: 10.1080/00016480701796944
  316. [316]
    Behrendt S, Beesdo-Baum K, Hofler M, Perkonigg A, Buhringer G, Lieb R, Wittchen HU (2012) The relevance of age at first alcohol and nicotine use for initiation of cannabis use and progression to cannabis use disorders. Drug Alcohol Depend 123 (1–3): 48–56. doi: 10.1016/j.drugalcdep.2011.10.013
  317. [317]
    Behrendt S, Wittchen HU, Höfler M, Lieb R, Beesdo K (2009) Transitions from first substance use to substance use disorders in adolescence: Is early onset associated with a rapid escalation? Drug Alcohol Depend 99 (1): 68–78. doi: https://doi.org/10.1016/j.drugalcdep.2008.06.014
  318. [318]
    Benyamina A, Kebir O, Blecha L, Reynaud M, Krebs MO (2011) CNR1 gene polymorphisms in addictive disorders: A systematic review and a meta-analysis. Addict Biol 16 (1): 1–6. doi: 10.1111/j.1369-1600.2009.00198.x
  319. [319]
    Blanco C, Hasin DS, Wall MM, Florez-Salamanca L, Hoertel N, Wang S, Kerridge BT, Olfson M (2016) Cannabis Use and Risk of Psychiatric Disorders: Prospective Evidence From a US National Longitudinal Study. JAMA Psychiat 73 (4): 388–395. doi: 10.1001/jamapsychiatry.2015.3229
  320. [320]
    Boden JM, Fergusson DM, Horwood LJ (2006) Illicit drug use and dependence in a New Zealand birth cohort. Aust NZ J Psychiatry 40 (2): 156–163. doi: 10.1080/j.1440-1614.2006.01763.x
  321. [321]
    Boden MT, Babson KA, Vujanovic AA, Short NA, Bonn-Miller MO (2013) Posttraumatic stress disorder and cannabis use characteristics among military veterans with cannabis dependence. Am J Addict 22 (3): 277–284. doi: 10.1111/j.1521-0391.2012.12018.x
  322. [322]
    Bonnet U, Preuss UW (2017) The cannabis withdrawal syndrome: current insights. Subst Abuse Rehabil 8: 9–37. doi: 10.2147/SAR.S109576
  323. [323]
    Budney AJ, Hughes JR (2006) The cannabis withdrawal syndrome. Curr Opin Psychiat 19 (3): 233–238. doi: 10.1097/01.yco.0000218592.00689.e5
  324. [324]
    Bühler KM, Giné E, Echeverry-Alzate V, Calleja-Conde J, de Fonseca FR, López-Moreno JA (2015) Common single nucleotide variants underlying drug addiction: More than a decade of research. Addict Biol 20 (5): 845–871. doi: 10.1111/adb.12204
  325. [325]
    BZgA (2015) Der Cannabiskonsum Jugendlicher und junger Erwachsener in Deutschland 2014. Ergebnisse einer aktuellen Repräsentativbefragung und Trends. Bundeszentrale für gesundheitliche Aufklärung. KölnGoogle Scholar
  326. [326]
    Calabria B, Degenhardt L, Briegleb C, Vos T, Hall W, Lynskey M, Callaghan B, Rana U, McLaren J (2010a) Systematic review of prospective studies investigating „remission” from amphetamine, cannabis, cocaine or opioid dependence. Addict Behav 35 (8): 741–749. doi: 10.1016/j.addbeh.2010.03.019
  327. [327]
    Calabria B, Degenhardt L, Hall W, Lynskey M (2010b) Does cannabis use increase the risk of death? Systematic review of epidemiological evidence on adverse effects of cannabis use. Drug Alcohol Rev 29 (3): 318–330Google Scholar
  328. [328]
    Chen C-Y, O’Brien MS, Anthony JC (2005) Who becomes cannabis dependent soon after onset of use? Epidemiological evidence from the United States: 2000–2001. Drug Alcohol Depend 79 (1): 11–22. doi: 10.1016/j.drugalcdep.2004.11.014
  329. [329]
    Coffey C, Carlin JB, Lynskey M, Li N, Patton GC (2003) Adolescent precursors of cannabis dependence: findings from the Victorian Adolescent Health Cohort Study. Br J Psychiat 182: 330–336Google Scholar
  330. [330]
    Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. JAMA 291 (17): 2114–2121. doi: 10.1001/jama.291.17.2114
  331. [331]
    Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ (2015) Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiat Res 66–67: 135–141. doi: 10.1016/j.jpsychires.2015.05.004
  332. [332]
    Cougle JR, Hakes JK, Macatee RJ, Zvolensky MJ, Chavarria J (2016) Probability and correlates of dependence among regular users of alcohol, nicotine, cannabis, and cocaine: concurrent and prospective analyses of the National Epidemiologic Survey on Alcohol and Related Conditions. J Clin Psychiat 77 (4): e444–450. doi: 10.4088/JCP.14m09469
  333. [333]
    de Dios MA, Vaughan EL, Stanton CA, Niaura R (2009) Adolescent tobacco use and substance abuse treatment outcomes. J Subst Abuse Treat 37 (1): 17–24. doi: 10.1016/j.jsat.2008.09.006
  334. [334]
    Degenhardt L, Hall W (2012) Extent of illicit drug use and dependence, and their contribution to the global burden of disease. The Lancet 379 (9810): 55–70. doi: 10.1016/S0140-6736(11)61138-0
  335. [335]
    Degenhardt L, Bucello C, Calabria B, Nelson P, Roberts A, Hall W, Lynskey M, Wiessing L (2011) What data are available on the extent of illicit drug use and dependence globally? Results of four systematic reviews. Drug Alcohol Depend 117 (2–3): 85–101. doi: 10.1016/j.drugalcdep.2010.11.032
  336. [336]
    Degenhardt L, Coffey C, Carlin JB, Swift W, Moore E, Patton GC (2010) Outcomes of occasional cannabis use in adolescence: 10-year follow-up study in Victoria, Australia. Br J Psychiat 196 (4): 290–295. doi: 10.1192/bjp.bp.108.056952
  337. [337]
    Degenhardt L, Ferrari AJ, Calabria B, Hall WD, Norman RE, McGrath J, Flaxman AD, Engell RE, Freedman GD, Whiteford HA, Vos T (2013a) The Global Epidemiology and Contribution of Cannabis Use and Dependence to the Global Burden of Disease: Results from the GBD 2010 Study. PloS one 8 (10) (no pagination) (e76635). doi: http://dx.doi.org/10.1371/journal.pone.0076635
  338. [338]
    Degenhardt L, Hall W (2001) The relationship between tobacco use, substance-use disorders and mental health: results from the National Survey of Mental Health and Well-being. Nicotine Tobacco Res 3 (3): 225–234. doi: 10.1080/14622200110050457
  339. [339]
    Degenhardt L, Whiteford HA, Ferrari AJ, Baxter AJ, Charlson FJ, Hall WD, Freedman G, Burstein R, Johns N, Engell RE, Flaxman A, Murray CJL, Vos T (2013b) Global burden of disease attributable to illicit drug use and dependence: Findings from the Global Burden of Disease Study 2010. Lancet 382 (9904): 1564–1574. doi: 10.1016/S0140-6736(13)61530-5
  340. [340]
    Dilling H, Mombour W, Schmidt MH (1992) Internationale Klassifikation psychischer Störungen. ICD-10 Kapitel V (F). Klinisch-diagnostiche Leitlinien. 7. Aufl. World Health Organization, GenevaGoogle Scholar
  341. [341]
    EMCDDA (2017) European Monitoring Centre for Drugs and Drug Addiction. European drug report: trends and developments [http://www.emcdda.europa.eu/publications/edr/trends-developments/2017_en]
  342. [342]
    Farmer RF, Kosty DB, Seeley JR, Duncan SC, Lynskey MT, Rohde P, Klein DN, Lewinsohn PM (2015) Natural course of cannabis use disorders. Psychol Med 45 (1): 63–72. doi: 10.1017/s003329171400107X
  343. [343]
    Feingold D, Weiser M, Rehm J, Lev-Ran S (2016) The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacol 26 (3): 493–505. doi: 10.1016/j.euroneuro.2015.12.037
  344. [344]
    Ford DE, Vu HT, Anthony JC (2002) Marijuana use and cessation of tobacco smoking in adults from a community sample. Drug Alcohol Depend 67 (3): 243–248Google Scholar
  345. [345]
    Gomes de Matos E, Atzendorf J, Kraus L, Piontek D (2016) Substanzkonsum in der Allgemeinbevölkerung in Deutschland. Ergebnisse des Epidemiologischen Suchtsurveys 2015. Sucht 62 (5): 271–281Google Scholar
  346. [346]
    Gossop M, Darke S, Griffiths P, Hando J., Powis B., Hall W, Strang J (1995) The Severity of Dependence Scale (SDS): psychometric properties of the SDS in English and Australian samples of heroin, cocaine and amphetamine users. Addiction 90 (5): 607–614Google Scholar
  347. [347]
    Gourlay SG, Forbes A, Marriner T, Pethica D, McNeil JJ (1994) Prospective study of factors predicting outcome of transdermal nicotine treatment in smoking cessation. Br Med J 309 (6958): 842–846Google Scholar
  348. [348]
    Grant JD, Scherrer JF, Neuman RJ, Todorov AA, Price RK, Bucholz KK (2006) A comparison of the latent class structure of cannabis problems among adult men and women who have used cannabis repeatedly. Addiction 101 (8): 1133–1142. doi: 10.1111/j.1360-0443.2006.01463.x
  349. [349]
    Gray KM, Riggs PD, Min SJ, Mikulich-Gilbertson SK, Bandyopadhyay D, Winhusen T (2011) Cigarette and cannabis use trajectories among adolescents in treatment for attention-deficit/hyperactivity disorder and substance use disorders. Drug Alcohol Depend 117 (2–3): 242–247. doi: 10.1016/j.drugalcdep.2011.02.005
  350. [350]
    Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ (2014a) Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 136: 158–161. doi: 10.1016/j.drugalcdep.2013.11.022
  351. [351]
    Haberstick BC, Young SE, Zeiger JS, Lessem JM, Hewitt JK, Hopfer CJ (2014b) Prevalence and correlates of alcohol and cannabis use disorders in the United States: results from the national longitudinal study of adolescent health. Drug Alcohol Depend 136: 158–161. doi: 10.1016/j.drugalcdep.2013.11.022
  352. [352]
    Hall W, Degenhardt L (2009) Adverse health effects of non-medical cannabis use. Lancet 374 (9698): 1383–1391Google Scholar
  353. [353]
    Hall W, Degenhardt L, Lynskey M (2001) The health and psychological consequences of cannabis use. Australian Publishing Service, CanberraGoogle Scholar
  354. [354]
    Hartz SM, Pato CN, Medeiros H, et al. (2014) Comorbidity of severe psychotic disorders with measures of substance use. JAMA Psychiat 71 (3): 248–254. doi: 10.1001/jamapsychiatry.2013.3726
  355. [355]
    Hasin DS, Saha TD, Kerridge BT, Goldstein RB, Chou SP, Zhang H, Jung J, Pickering RP, Ruan WJ, Smith SM, Huang B, Grant BF (2015) Prevalence of Marijuana Use Disorders in the United States Between 2001–2002 and 2012–2013. JAMA Psychiat 72 (12): 1235–1242. doi: 10.1001/jamapsychiatry.2015.1858
  356. [356]
    Haskins A, Bertone-Johnson E, Pekow P, Carbone E, Chasan-Taber L (2010) Correlates of smoking cessation at pregnancy onset among Hispanic women in Massachusetts. American journal of health promotion: AJHP 25 (2): 100–108. doi: 10.4278/ajhp.090223-QUAN-77
  357. [357]
    Hayatbakhsh MR, Najman JM, Jamrozik K, Mamun AA, O’Callaghan MJ, Williams GM (2009) Childhood sexual abuse and cannabis use in early adulthood: findings from an Australian birth cohort study. Arch Sex Beh 38 (1): 135–142. doi: 10.1007/s10508-007-9172-5
  358. [358]
    Hoch E, Petersen K, Thomasius R (2016) Cannabis. In: Batra A, Bilke-Hentsch O (eds) Praxisbuch Sucht. Therapie der Suchterkrankungen im Jugend- und Erwachsenenalter. Thieme, Stuttgart New YorkGoogle Scholar
  359. [359]
    Huestis MA (2007) Human cannabinoid pharmacokinetics. Chem Biodivers 4 (8): 1770–1804. doi: 10.1002/cbdv.200790152
  360. [360]
    Humfleet G, Munoz R, Sees K, Reus V, Hall S (1999) History of alcohol or drug problems, current use of alcohol or marijuana, and success in quitting smoking. Addict Behav 24 (1): 149–154Google Scholar
  361. [361]
    Humphreys KL, Eng T, Lee SS (2013) Stimulant medication and substance use outcomes: A meta-analysis. JAMA Psychiat 70 (7): 740–749. doi: 10.1001/jamapsychiatry.2013.1273
  362. [362]
    Iversen L (2003) Cannabis and the brain. Brain 126 (Pt 6): 1252–1270Google Scholar
  363. [363]
    Kandel D (1975) Stages in adolescent involvement in drug use. Science 190 (4217): 912–914Google Scholar
  364. [364]
    Kandel D, Faust R (1975) Sequence and stages in patterns of adolescent drug use. Arch Gen Psychiat 32 (7): 923–932Google Scholar
  365. [365]
    Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiat 14. doi: 10.1186/1471-244X-14-136
  366. [366]
    Kelly E, Darke S, Ross J (2004) A review of drug use and driving: epidemiology, impairment, risk factors and risk perceptions. Drug Alcohol Rev 23 (3): 319–344Google Scholar
  367. [367]
    Kraus L, Pabst A, Gomes de Matos E, Piontek D (2014) Kurzbericht Epidemiologischer Suchtsurvey 2012. Tabellenband: Prävalenz des Konsums illegaler Drogen, multipler Drogenerfahrung und drogenbezogener Störungen nach Geschlecht und Alter im Jahr 2012. IFT Institut für Therapieforschung, MünchenGoogle Scholar
  368. [368]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  369. [369]
    Macleod J, Oakes R, Copello A, Crome I, Egger M, Hickman M, Oppenkowski T, Stokes-Lampard H, Smith GD (2004) Psychological and social sequelae of cannabis and other illicit drug use by young people: A systematic review of longitudinal, general population studies. Lancet 363 (9421): 1579–1588. doi: 10.1016/S0140-6736(04)16200-4
  370. [370]
    Metrik J, Spillane NS, Leventhal AM, Kahler CW (2011) Marijuana use and tobacco smoking cessation among heavy alcohol drinkers. Drug Alcohol Depend 119 (3): 194–200. doi: 10.1016/j.drugalcdep.2011.06.004
  371. [371]
    Montanari L, Guarita B, Mounteney J, Zipfel N, Simon R (2017) Cannabis Use among People Entering Drug Treatment in Europe: A Growing Phenomenon? Eur Addict Res 23 (3): 113–121Google Scholar
  372. [372]
    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3
  373. [373]
    National Academies of Sciences E, and Medicine. (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. The National Academies Press, Washington, DC. doi: 10.17226/24625.
  374. [374]
    Newcomb MD, Galaif ER, Locke TF (2001) Substance use diagnoses within a community sample of adults: Distinction, comorbidity, and progression over time. Profess Psychol Res Pract 32 (3): 239Google Scholar
  375. [375]
    OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford
  376. [376]
    Pacek LR, Martins SS, Crum RM (2013) The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: Results from a national sample. J Affect Disord 148 (2–3): 188–195. doi: http://dx.doi.org/10.1016/j.jad.2012.11.059
  377. [377]
    Patton GC, Coffey C, Carlin JB, Sawyer SM, Lynskey M (2005) Reverse gateways? Frequent cannabis use as a predictor of tobacco initiation and nicotine dependence. Addiction 100 (10): 1518–1525. doi: 10.1111/j.1360-0443.2005.01220.x
  378. [378]
    Patton GC, Coffey C, Carlin JB, Sawyer SM, Wakefield M (2006) Teen smokers reach their mid twenties. J Adolesc Health 39 (2): 214–220. doi: 10.1016/j.jadohealth.2005.11.027
  379. [379]
    Peer K, Rennert L, Lynch KG, Farrer L, Gelernter J, Kranzler HR (2013) Prevalence of DSM-IV and DSM-5 alcohol, cocaine, opioid, and cannabis use disorders in a largely substance dependent sample. Drug Alcohol Depend 127 (1): 215–219Google Scholar
  380. [380]
    Perkonigg A, Goodwin RD, Fiedler A, Behrendt S, Beesdo K, Lieb R, Wittchen HU (2008) The natural course of cannabis use, abuse and dependence during the first decades of life. Addiction 103 (3): 439–449Google Scholar
  381. [381]
    Peters EN, Budney AJ, Carroll KM (2012) Clinical correlates of co-occurring cannabis and tobacco use: a systematic review. Addiction 107 (8): 1404–1417. doi: http://dx.doi.org/10.1111/j.1360-0443.2012.03843.x
  382. [382]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch, vol 2006. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. Ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengerichGoogle Scholar
  383. [383]
    Pingault JB, Cote SM, Galera C, Genolini C, Falissard B, Vitaro F, Tremblay RE (2013) Childhood trajectories of inattention, hyperactivity and oppositional behaviors and prediction of substance abuse/dependence: a 15-year longitudinal population-based study. Mol Psychiat 18 (7): 806–812. doi: 10.1038/mp.2012.87
  384. [384]
    Ramesh D, Schlosburg JE, Wiebelhaus JM, Lichtman AH (2011) Marijuana Dependence: Not Just Smoke and Mirrors. ILAR journal/National Research Council, Institute of Laboratory Animal Resources 52 (3): 295–308. doi: 10.1093/ilar.52.3.295
  385. [385]
    Rummel C, Budde A, Schulte L, Dammer E, Karachaliou K, Pfeiffer-Gerschel T (2016) 2016 National report (2015 data) to the EMCDDA by the REITOX National Focal Point. Germany, Workbook Treatment. Deutsche Beobachtungsstelle für Drogen und Drogensucht DBDD., MunichGoogle Scholar
  386. [386]
    Schwantes-An T-H, Zhang J, Chen L-S, Hartz SM, Culverhouse RC, Chen X, Coon H, Frank J, Kamens HM, Konte B, Kovanen L, Latvala A, Legrand LN, Maher BS, Melroy WE, Nelson EC, Reid MW, Robinson JD, Shen P-H, Yang B-Z, Andrews JA, Aveyard P, Beltcheva O, Brown SA, Cannon DS, Cichon S, Corley RP, Dahmen N, Degenhardt L, Foroud T, Gaebel W, Giegling I, Glatt SJ, Grucza RA, Hardin J, Hartmann AM, Heath AC, Herms S, Hodgkinson CA, Hoffmann P, Hops H, Huizinga D, Ising M, Johnson EO, Johnstone E, Kaneva RP, Kendler KS, Kiefer F, Kranzler HR, Krauter KS, Levran O, Lucae S, Lynskey MT, Maier W, Mann K, Martin NG, Mattheisen M, Montgomery GW, Müller-Myhsok B, Murphy MF, Neale MC, Nikolov MA, Nishita D, Nöthen MM, Nurnberger J, Partonen T, Pergadia ML, Reynolds M, Ridinger M, Rose RJ, Rouvinen-Lagerström N, Scherbaum N, Schmäl C, Soyka M, Stallings MC, Steffens M, Treutlein J, Tsuang M, Wall TL, Wodarz N, Yuferov V, Zill P, Bergen AW, Chen J, Cinciripini PM, Edenberg HJ, Ehringer MA, Ferrell RE, Gelernter J, Goldman D, Hewitt JK, Hopfer CJ, Iacono WG, Kaprio J, Kreek MJ, Kremensky IM, Madden PAF, McGue M, Munafò MR, Philibert RA, Rietschel M, Roy A, Rujescu D, Saarikoski ST, Swan GE, Todorov AA, Vanyukov MM, Weiss RB, Bierut LJ, Saccone NL (2015) Association of the oprm1 variant rs1799971 (a118g) with non-specific liability to substance dependence in a collaborative de novo meta-analysis of european-ancestry cohorts. Behav Genet. doi: 10.1007/s10519-015-9737-3
  387. [387]
    Sharma P, Murthy P, Bharath MM (2012) Chemistry, metabolism, and toxicology of cannabis: clinical implications. Iran J Psychiat 7 (4): 149–156Google Scholar
  388. [388]
    SIGN (2015) Scottish Intercollegiate Guidelines Network, SIGN 50 Methodology Checklist. Edinburgh, United KingdomGoogle Scholar
  389. [389]
    Silins E, Horwood LJ, Patton GC, Fergusson DM, Olsson CA, Hutchinson DM, Spry E, Toumbourou JW, Degenhardt L, Swift W, Coffey C, Tait RJ, Letcher P, Copeland J, Mattick RP (2014) Young adult sequelae of adolescent cannabis use: an integrative analysis. Lancet Psychiat 1 (4): 286–293. doi: https://doi.org/10.1016/S2215-0366(14)70307-4
  390. [390]
    Smith-Kielland A, Skuterud B, Morland J (1999) Urinary excretion of 11-nor-9-carboxy-delta9-tetrahydrocannabinol and cannabinoids in frequent and infrequent drug users. J Anal Toxicol 23 (5): 323–332Google Scholar
  391. [391]
    Stapleton JA, Keaney F, Sutherland G (2009) Illicit drug use as a predictor of smoking cessation treatment outcome. Nicotine Tobacco Res 11 (6): 685–689. doi: 10.1093/ntr/ntp050
  392. [392]
    Swift W, Coffey C, Carlin JB, Degenhardt L, Patton GC (2008) Adolescent cannabis users at 24 years: trajectories to regular weekly use and dependence in young adulthood. Addiction (Abingdon, England) 103 (8): 1361–1370. doi: 10.1111/j.1360-0443.2008.02246.x
  393. [393]
    Timberlake DS (2009) A comparison of drug use and dependence between blunt smokers and other cannabis users. Subst Use Misuse 44 (3): 401–415. doi: 10.1080/10826080802347651
  394. [394]
    Timberlake DS, Haberstick BC, Hopfer CJ, Bricker J, Sakai JT, Lessem JM, Hewitt JK (2007) Progression from marijuana use to daily smoking and nicotine dependence in a national sample of U.S. adolescents. Drug Alcohol Depend 88 (2–3): 272–281. doi: 10.1016/j.drugalcdep.2006.11.005
  395. [395]
    United Nations Office on Drugs and Crime (2017) World drug report. United Nations Office on Drugs and Crime, Vienna, AustriaGoogle Scholar
  396. [396]
    Walsh K, Elliott JC, Shmulewitz D, Aharonovich E, Strous R, Frisch A, Weizman A, Spivak B, Grant BF, Hasin D (2014) Trauma exposure, posttraumatic stress disorder and risk for alcohol, nicotine, and marijuana dependence in Israel. Comprehens Psychiat 55 (3): 621–630. doi: 10.1016/j.comppsych.2013.11.016
  397. [397]
    Wittchen HU, Frohlich C, Behrendt S, Gunther A, Rehm J, Zimmermann P, Lieb R, Perkonigg A (2007) Cannabis use and cannabis use disorders and their relationship to mental disorders: a 10-year prospective-longitudinal community study in adolescents. Drug Alcohol Depend 88 Suppl 1: S60–70. doi: 10.1016/j.drugalcdep.2006.12.013
  398. [398]
    Wong A, Montebello ME, Norberg MM, Rooney K, Lintzeris N, Bruno R, Booth J, Arnold JC, McGregor IS (2013) Exercise increases plasma THC concentrations in regular cannabis users. Drug Alcohol Depend 133 (2): 763–767. doi: 10.1016/j.drugalcdep.2013.07.031
  399. [399]
    APA – American Psychiatric Association (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  400. [400]
    Baldacchino A, Hughes Z, Kehoe M, Blair H, Teh Y, Windeatt S, Crome IB (2012) Cannabis psychosis: examining the evidence for a distinctive psychopathology in a systematic and narrative review. Am J Addict 21 Suppl 1: S88–98. doi: 10.1111/j.1521-0391.2012.00295.x
  401. [401]
    Ben Amar M, Potvin S (2007) Cannabis and psychosis: what is the link? J Psychoact Drugs 39 (2): 131–142Google Scholar
  402. [402]
    Burns JK (2012) Cannabis use and duration of untreated psychosis: a systematic review and meta-analysis. Curr Pharm Des 18 (32): 5093–5104Google Scholar
  403. [403]
    Cookey J, Bernier D, Tibbo PG (2014) White matter changes in early phase schizophrenia and cannabis use: An update and systematic review of diffusion tensor imaging studies. Schizophrenia Research 156 (2–3): 137–142. doi: http://dx.doi.org/10.1016/j.schres.2014.04.026
  404. [404]
    Elm E, Altman D, Egger M, Pocock S, Gøtzsche P, Vandenbroucke J (2008) The Strengthening the Reporting of Observational Studies in Epidemiology[STROBE] statement: guidelines for reporting observational studies. Gaceta Sanitaria 22: 144–150.Google Scholar
  405. [405]
    Ferretjans R, Moreira FA, Teixeira AL, Salgado JV (2012) The endocannabinoid system and its role in schizophrenia: A systematic review of the literature. Rev Bras Psiquiat 34 (Suppl 2): S163-S193. doi: 10.1016/j.rbp.2012.07.003
  406. [406]
    Geoffroy PA, Etain B, Houenou J (2013) Gene x environment interactions in schizophrenia and bipolar disorder: Evidence from neuroimaging. Front Psychiat 14,4: 136Google Scholar
  407. [407]
    Goes FS (2016) Genetics of Bipolar Disorder: Recent Update and Future Directions. Psychiat Clin N Am 39 (1): 139–155. doi: 10.1016/j.psc.2015.10.004
  408. [408]
    Jacobi F, Höfler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen H-U (2014) Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 85: 77–87Google Scholar
  409. [409]
    James A, James C, Thwaites T (2013) The brain effects of cannabis in healthy adolescents and in adolescents with schizophrenia: a systematic review. Psychiat Res 214 (3): 181–189. doi: http://dx.doi.org/10.1016/j.pscychresns.2013.07.012
  410. [410]
    Janzarik W (2003) Der Psychose-Begriff und die Qualität des Psychotischen. Nervenarzt 74 (1): 3–11. doi: https://doi.org/10.1007/s00115–002–1348–6
  411. [411]
    Koskinen J, Lohonen J, Koponen H, Isohanni M, Miettunen J (2010) Rate of cannabis use disorders in clinical samples of patients with schizophrenia: A meta-analysis. Schizophren Bull 36 (6): 1115–1130. doi: http://dx.doi.org/10.1093/schbul/sbp031
  412. [412]
    Kraan T, Velthorst E, Koenders L, Zwaart K, Ising HK, van den Berg D, de Haan L, van der Gaag M (2015) Cannabis use and transition to psychosis in individuals at ultra-high risk: Review and meta-analysis. Psychol Med 46, 4: 673–681 doi: 10.1017/S0033291715002329
  413. [413]
    Large M, Sharma S, Compton MT, Slade T, Nielssen O (2011) Cannabis use and earlier onset of psychosis: A systematic meta-analysis. Arch Gen Psychiat 68 (6): 555–561. doi: http://dx.doi.org/10.1001/archgenpsychiatry.2011.5
  414. [414]
    Leweke FM, Koethe D (2008) Cannabis and psychiatric disorders: it is not only addiction. Addict Biol 13 (2): 264–275. doi: 10.1111/j.1369-1600.2008.00106.x
  415. [415]
    Linscott RJ, van Os J (2013) An updated and conservative systematic review and meta-analysis of epidemiological evidence on psychotic experiences in children and adults: On the pathway from proneness to persistence to dimensional expression across mental disorders. Psychol Med 43 (6): 1133–1149Google Scholar
  416. [416]
    Malchow B, Hasan A, Fusar-Poli P, Schmitt A, Falkai P, Wobrock T (2013) Cannabis abuse and brain morphology in schizophrenia: A review of the available evidence. Eur Arch Psychiat Clin Neurosci 263 (1): 3–13. doi: http://dx.doi.org/10.1007/s00406-012-0346-3
  417. [417]
    Marconi A, Di Forti M, Lewis CM, Murray RM, Vassos E (2016) Meta-analysis of the association between the level of cannabis use and risk of psychosis. Schizophr Bul. doi: 10.1093/schbul/sbw003
  418. [418]
    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3
  419. [419]
    Myles H, Myles N, Large M (2016) Cannabis use in first episode psychosis: Meta-analysis of prevalence, and the time course of initiation and continued use. Aust NZ J Psychiat 50 (3): 208–219. doi: 10.1177/0004867415599846
  420. [420]
    Myles N, Newall H, Nielssen O, Large M (2012) The association between cannabis use and earlier age at onset of schizophrenia and other psychoses: meta-analysis of possible confounding factors. Curr Pharm Des 18 (32): 5055–5069Google Scholar
  421. [421]
    Network SIG (2015) SIGN 50: a guideline developer’s handbook. SIGN, EdinburghGoogle Scholar
  422. [422]
    OCEBM LoEWG (2011) The Oxford 2011 Levels of Evidence. Oxford Centre for Evidence-Based Medicine, OxfordGoogle Scholar
  423. [423]
    Peters UH (2011) Lexikon. Psychiatrie, Psychotherapie, medizinische Psychologie. Elsevier. Urban & Fischer, MünchenGoogle Scholar
  424. [424]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und -missbrauch. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. 1 systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengerichGoogle Scholar
  425. [425]
    Potvin S, Sepehry AA, Stip E (2006) A meta-analysis of negative symptoms in dual diagnosis schizophrenia. Psychol Med 36 (4): 431–440. doi: 10.1017/S003329170500574X
  426. [426]
    Potvin S, Sepehry AA, Stip E (2007) Meta-analysis of depressive symptoms in dual-diagnosis schizophrenia. Aust NZ J Psychiat 41 (10): 792–799. doi: 10.1080/00048670701579041
  427. [427]
    Rapp C, Bugra H, Riecher-Rossler A, Tamagni C, Borgwardt S (2012) Effects of cannabis use on human brain structure in psychosis: a systematic review combining in vivo structural neuroimaging and post mortem studies. Curr Pharm Des 18 (32): 5070–5080Google Scholar
  428. [428]
    Sara GE, Large MM, Matheson SL, Burgess PM, Malhi GS, Whiteford HA, Hall WD (2015) Stimulant use disorders in people with psychosis: A meta-analysis of rate and factors affecting variation. Aust NZ J Psychiat 49 (2): 106–117. doi: 10.1177/0004867414561526
  429. [429]
    Schoeler T, Monk A (2016).Google Scholar
  430. [430]
    Semple DM, McIntosh AM, Lawrie SM (2005) Cannabis as a risk factor for psychosis: Systematic review. J Psychopharmacol 19 (2): 187–194. doi: 10.1177/0269881105049040
  431. [431]
    Serafini G, Pompili M, Innamorati M, Rihmer Z, Sher L, Girardi P (2012) Can cannabis increase the suicide risk in psychosis? A critical review. Curr Pharm Des 18 (32): 5165–5187Google Scholar
  432. [432]
    Szoke A, Galliot AM, Richard JR, Ferchiou A, Baudin G, Leboyer M, Schurhoff F (2014) Association between cannabis use and schizotypal dimensions – A meta-analysis of cross-sectional studies. Psychiat Res 219 (1): 58–66. doi: http://dx.doi.org/10.1016/j.psychres.2014.05.008
  433. [433]
    Uliana V, Tomassini A, Pollice R, Gennarelli M, Faravelli F, Casacchia M, Di Maria E (2013) Cannabis and psychosis: A systematic review of genetic studies. Curr Psychiat Rev 9 (4): 302–315Google Scholar
  434. [434]
    Zammit S, Moore THM, Lingford-Hughes A, Barnes TRE, Jones PB, Burke M, Lewis G (2008) Effects of cannabis use on outcomes of psychotic disorders: Systematic review. Br J Psychiat 193 (5): 357–363. doi: http://dx.doi.org/10.1192/bjp.bp.107.046375
  435. [435]
    Zondervan KT (2011) Genetic Association Study Design. In: Zeggini E, Morris A (eds) Analysis of Complex Disease Association Studies. Elsevir, Burlington, MA, USA, pp 25–47Google Scholar
  436. [436]
    APA (American Psychiatric Association) (ed) (1994) Diagnostic and Statistical Manual of Mental Disorders, 4th edn. American Psychiatric Association, Washington, DCGoogle Scholar
  437. [437]
    Baggio S, N’Goran AA, Deline S, Studer J, Dupuis M, Henchoz Y, Mohler-Kuo M, Daeppen JB, Gmel G (2014) Patterns of cannabis use and prospective associations with health issues among young males. Addiction 109 (6): 937–945. doi: 10.1111/add.12490
  438. [438]
    Borowsky IW, Ireland M, Resnick MD (2001) Adolescent suicide attempts: risks and protectors. Pediatrics 107: 485–493Google Scholar
  439. [439]
    Brook J, Rosen Z, Brook D (2001) The effect of early marijuana use on later anxiety and depressive symptoms. NYS Psychologist (New York): 35–40Google Scholar
  440. [440]
    Brook JS, Cohen P, Brook DW (1998) Longitudinal study of co-occurring psychiatric disorders and substance use. J Am Acad Child Adolesc Psychiat 37: 322–330Google Scholar
  441. [441]
    Cairns KE, Yap MBH, Pilkington PD, Jorm AF (2014) Risk and protective factors for depression that adolescents can modify: A systematic review and meta-analysis of longitudinal studies. J Affect Disord 169: 61–75. doi: 10.1016/j.jad.2014.08.006
  442. [442]
    Cougle JR, Hakes JK, Macatee RJ, Chavarria J, Zvolensky MJ (2015) Quality of life and risk of psychiatric disorders among regular users of alcohol, nicotine, and cannabis: An analysis of the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Psychiat Res 66–67: 135–141. doi: 10.1016/j.jpsychires.2015.05.004
  443. [443]
    Danielsson A-K, Lundin A, Agardh E, Allebeck P, Forsell Y (2016) Cannabis use, depression and anxiety: A 3-year prospective population-based study. J Affect Disord 193: 103–108. doi: 10.1016/j.jad.2015.12.045
  444. [444]
    Degenhardt L, Coffey C, Romaniuk H, Swift W, Carlin JB, Hall WD, Patton GC (2013) The persistence of the association between adolescent cannabis use and common mental disorders into young adulthood. Addiction (Abingdon, England) 108 (1): 124–133. doi: http://dx.doi.org/10.1111/j.1360-0443.2012.04015.x
  445. [445]
    Dilling H, Mombour W, Schmidt MH (2010) Internationale Klassifikation psychischer Störungen. ICD-10. Huber, BernGoogle Scholar
  446. [446]
    EMCDDA (2016) Europäischer Drogenbericht 2016: Trends und Entwicklungen; Europäische Beobachtungsstelle für Drogen und Drogensucht. LuxemburgGoogle Scholar
  447. [447]
    Feingold D, Weiser M, Rehm J, Lev-Ran S (2015) The association between cannabis use and mood disorders: A longitudinal study J Affect Disord 172: 211–218Google Scholar
  448. [448]
    Feingold D, Weiser M, Rehm J, Lev-Ran S (2016) The association between cannabis use and anxiety disorders: Results from a population-based representative sample. Eur Neuropsychopharmacol 26 (3): 493–505. doi: 10.1016/j.euroneuro.2015.12.037
  449. [449]
    Fergusson DM, Horwood LJ, Swain-Campbell N, (2002) Cannabis use and psychosocial adjustment in adolescence and young adulthood. Addiction 97: 1123–1135Google Scholar
  450. [450]
    Gibbs M, Winsper C, Marwaha S, Gilbert E, Broome M, Singh SP (2015) Cannabis use and mania symptoms: a systematic review and meta-analysis. J Affect Disord 171: 39–47. doi: http://dx.doi.org/10.1016/j.jad.2014.09.016
  451. [451]
    Henquet C, Krabbendam L, De Graaf R, Ten Have M, Van Os J (2006) Cannabis use and expression of mania in the general population. J Affect Disord 95: 103–110Google Scholar
  452. [452]
    Jacobi F, Höfler M, Strehle J, Mack S, Gerschler A, Scholl L, Busch MA, Maske U, Hapke U, Gaebel W, Maier W, Wagner M, Zielasek J, Wittchen H-U (2014) Psychische Störungen in der Allgemeinbevölkerung. Nervenarzt 85: 77–87Google Scholar
  453. [453]
    Juon HS, Ensminger ME (1997) Childhood, adolescent, and young adult predictors of suicidal behaviors: a prospective study of African Americans. J Child Psychol Psychiat 38: 553–563.Google Scholar
  454. [454]
    Kedzior KK, Laeber LT (2014) A positive association between anxiety disorders and cannabis use or cannabis use disorders in the general population- A meta-analysis of 31 studies. BMC Psychiat 14. doi: 10.1186/1471-244X-14-136
  455. [455]
    Lev-Ran S, Roerecke M, Le Foll B, George TP, McKenzie K, Rehm J (2014) The association between cannabis use and depression: a systematic review and meta-analysis of longitudinal studies. Psychol Med 44 (4): 797–810. doi: http://dx.doi.org/10.1017/S0033291713001438
  456. [456]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  457. [457]
    Moore TH, Zammit S, Lingford-Hughes A, Barnes TR, Jones PB, Burke M, Lewis G (2007) Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. Lancet 370 (9584): 319–328. doi: http://dx.doi.org/10.1016/S0140-6736%2807%2961162-3
  458. [458]
    Newcomb MD, Scheier LM, Bentler PM (1993) Effects of adolescent drug use on adult mental health: a prospective study of a community sample. Exp Clin Psychopharmacol 1: 215–241Google Scholar
  459. [459]
    Newcomb MD, Vargas-Carmona J, Galaif ER (1999) Drug problems and psychological distress among a community sample of adults: predictors, consequences, or confound? . J Commun Psychol 27: 405–429Google Scholar
  460. [460]
    OCEBM (2011) Levels of Evidence Working Group. The Oxford Levels of Evidence 2. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford
  461. [461]
    Pacek LR, Martins SS, Crum RM (2013) The bidirectional relationships between alcohol, cannabis, co-occurring alcohol and cannabis use disorders with major depressive disorder: Results from a national sample. J Affect Disord 148 (2–3): 188–195. doi: http://dx.doi.org/10.1016/j.jad.2012.11.059
  462. [462]
    Petersen KU, Thomasius R (2007) Auwirkungen von Cannabiskonsum und -missbrauch. Eine Expertise zu gesundheitlichen und psychosozialen Folgen. 1 systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publishers, LengerichGoogle Scholar
  463. [463]
    Renault PF, Schuster CR, Freedman DX, Sikic B, de Mello DN (1974) Repeat administration of marihuana smoke to humans. Arch Gen Psychiat 31: 95–102Google Scholar
  464. [464]
    Saban A, Flisher AJ, Grimsrud A, Morojele N, London L, Williams DR, Stein DJ (2014) The association between substance use and common mental disorders in young adults: results from the South African Stress and Health (SASH) Survey. Pan Afr Med J 17 Suppl 1: 11–11. doi: 10.11694/pamj.supp.2014.17.1.3328
  465. [465]
    SIGN (Scottish Intercollegiate Guidelines Network) (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United KingdomGoogle Scholar
  466. [466]
    Tijssen MJ, VanOs J, Wittchen H-U, Lieb R, Beesdo K, Wichers M (2010) Risk factors predicting onset and persistence of subthreshold expression of bipolar psychopathology among youth from the community. Acta Psychiat Scand 122: 255–266Google Scholar
  467. [467]
    Tyler E, Jones S, Black N, Carter LA, Barrowclough C (2015) The relationship between bipolar disorder and cannabis use in daily life: an experience sampling study.[Erratum appears in PLoS One. 2015;10 (3): e0123953; PMID: 25822166]. PLoS ONE [Electronic Resource] 10 (3): e0118916. doi: http://dx.doi.org/10.1371/journal.pone.0118916
  468. [468]
    Wilcox HC (2003) The development of suicide ideation and attempt: an epidemiologic study of fi rst graders followed into young adulthood. PhD thesis, John Hopkins UniversityGoogle Scholar
  469. [469]
    AIHW (Australian Institute of Health and Welfare) (2014) 2013 National Drug Strategy Household Survey: Detailed Report. Australian Institute of Health and Welfare, CanberraGoogle Scholar
  470. [470]
    Auwarter V, Dresen S, Weinmann W, Muller M, Putz M, Ferreiros N (2009) „Spice” and other herbal blends: harmless incense or cannabinoid designer drugs? J Mass Spectromet JMS 44 (5): 832–837. doi: 10.1002/jms.1558
  471. [471]
    Bonnet U, Mahler H (2015) Synthetic cannabinoids: spread, addiction biology & current perspective of personal health hazard. Fortschr Neurol Psychiatr 83 (4): 221–231. doi: 10.1055/s-0034-1399307
  472. [472]
    Brewer TL, Collins M (2014) A review of clinical manifestations in adolescent and young adults after use of synthetic cannabinoids. J Specialist Pediat Nurs JSPN 19 (2): 119–126. doi: 10.1111/jspn.12057
  473. [473]
    Castaneto MS, Gorelick DA, Desrosiers NA, Hartman RL, Pirard S, Huestis MA (2014) Synthetic cannabinoids: Epidemiology, pharmacodynamics, and clinical implications. Drug Alcohol Depend 144: 12–41. doi: 10.1016/j.drugalcdep.2014.08.005
  474. [474]
    Castellanos D, Gralnik LM (2016) Synthetic cannabinoids 2015: An update for pediatricians in clinical practice. World J Clin Pediat 5 (1): 16Google Scholar
  475. [475]
    Castellanos D, Singh S, Thornton G, Avila M, Moreno A (2011) Synthetic cannabinoid use: a case series of adolescents. J Adolescent Health 49 (4): 347–349Google Scholar
  476. [476]
    Coca SG, Singanamala S, Parikh CR (2012) Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Kidney Int 81 (5): 442–448Google Scholar
  477. [477]
    Forrester M, Kleinschmidt K, Schwarz E, Young A (2012) Synthetic cannabinoid and marijuana exposures reported to poison centers. Human Exp Toxicol 0960327111421945Google Scholar
  478. [478]
    Giroud C, de Cesare M, Berthet A, Varlet V, Concha-Lozano N, Favrat B (2015) E-Cigarettes: A Review of New Trends in Cannabis Use. Int J Environ Res Public Health 12 (8): 9988–10008. doi: 10.3390/ijerph120809988
  479. [479]
    Gunderson EW, Haughey HM, Ait-Daoud N, Joshi AS, Hart CL (2012) „Spice” and „K2” Herbal Highs: A Case Series and Systematic Review of the Clinical Effects and Biopsychosocial Implications of Synthetic Cannabinoid Use in Humans. Am J Addict 21 (4): 320–326. doi: 10.1111/j.1521-0391.2012.00240.x
  480. [480]
    Hopkins CY, Gilchrist BL (2013) A case of cannabinoid hyperemesis syndrome caused by synthetic cannabinoids. J Emerg Med 45 (4): 544–546Google Scholar
  481. [481]
    Lewin S, Glenton C, Munthe-Kaas H, Carlsen B, Colvin CJ, Gulmezoglu M, Noyes J, Booth A, Garside R, Rashidian A (2015) Using qualitative evidence in decision making for health and social interventions: an approach to assess confidence in findings from qualitative evidence syntheses (GRADE-CERQual). PLoS Med 12 (10): e1001895. doi: 10.1371/journal.pmed.1001895
  482. [482]
    Logan B, Reinhold L, Kacinko S (2011) K2 and Beyond: A Synthetic Cannabinoid Primer (K43). In: American Academy of Forensic Sciences, pp 21–26Google Scholar
  483. [483]
    OCEBM (2011) The Oxford Levels of Evidence 2. Levels of Evicence Working Group. http://www.cebm.net/index.aspx?o = 5653, 2 edn. Oxford Centre for Evidence-Based Medicine, Oxford
  484. [484]
    Pabst A, Piontek D, Kraus L, Müller S (2010) Substance use and substance use disorders: results of the 2009 epidemiological survey of substance abuse. Sucht 56: 327–336Google Scholar
  485. [485]
    Papanti D, Schifano F, Botteon G, Bertossi F, Mannix J, Vidoni D, Impagnatiello M, Pascolo-Fabrici E, Bonavigo T (2013) „Spiceophrenia”: A systematic overview of „Spice”-related psychopathological issues and a case report. Human Psychopharmacol Clin Exp 28 (4): 379–389. doi: 10.1002/hup.2312
  486. [486]
    Papaseit E, Farré M, Schifano F, Torrens M (2014) Emerging drugs in Europe. Curr Opin Psychiat 27 (4): 243–250. doi: 10.1097/YCO.0000000000000071
  487. [487]
    Petersen KU, Thomasius R (2007) Auswirkungen von Cannabiskonsum und-missbrauch: eine Expertise zu gesundheitlichen und psychosozialen Folgen; ein systematisches Review der international publizierten Studien von 1996–2006. Pabst Science Publ., LengerichGoogle Scholar
  488. [488]
    Plumb J, McDonnell WM, Anderson KT, Crouch BI, Caravati EM Adverse effects from pediatric exposures to spice (cannabinoid agonists). In: Clinical Toxicology, 2012. vol 7. Informa Healthcare 52 Vanderbilt Ave, New York, NY 10017 USA, pp 708–708Google Scholar
  489. [489]
    SIGN (2015) Scottish Intercollegiate Guidelines Network 50 Methodology Checklist. Edinburgh, United KingdomGoogle Scholar
  490. [490]
    Smith K, Flatley J (2011) Drug misuse declared: findings from the 2010/11 British crime survey. England and Wales Home Office 27Google Scholar
  491. [491]
    Tait RJ, Caldicott D, Mountain D, Hill SL, Lenton S (2016) A systematic review of adverse events arising from the use of synthetic cannabinoids and their associated treatment. Clin Toxicol (Philadelphia) 54 (1): 1–13. doi: 10.3109/15563650.2015.1110590
  492. [492]
    Teske J, Weller J-P, Fieguth A, Rothämel T, Schulz Y, Tröger HD (2010) Sensitive and rapid quantification of the cannabinoid receptor agonist naphthalen-1-yl- (1-pentylindol-3-yl) methanone (JWH-018) in human serum by liquid chromatography-tandem mass spectrometry. J Chromatogr B 878 (27): 2659–2663Google Scholar
  493. [493]
    Ukaigwe A, Karmacharya P, Donato A (2014) A gut gone to pot: A case of cannabinoid hyperemesis syndrome due to K2, a synthetic cannabinoid. Case Rep Emerg Med 2014Google Scholar
  494. [494]
    van Amsterdam J, Brunt T, van den Brink W (2015) The adverse health effects of synthetic cannabinoids with emphasis on psychosis-like effects. J Psychopharmacol 29 (3): 254–263. doi: 10.1177/0269881114565142
  495. [495]
    Winstock A, Lynskey M, Borschmann R, Waldron J (2015) Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample. J Psychopharmacol 29 (6): 698–703. doi: 10.1177/0269881115574493
  496. [496]
    Winstock AR, Barratt MJ (2013) The 12-month prevalence and nature of adverse experiences resulting in emergency medical presentations associated with the use of synthetic cannabinoid products. Human Psychopharmacol Clin Exp 28 (4): 390–393Google Scholar

Copyright information

© Springer-Verlag GmbH Deutschland, ein Teil von Springer Nature 2019

Authors and Affiliations

  • Miriam Schneider
    • 1
  • Chris Maria Friemel
    • 2
  • Rupert von Keller
    • 2
  • Kristina Adorjan
    • 3
  • Udo Bonnet
    • 4
  • Alkomiet Hasan
    • 3
  • Derik Hermann
    • 5
  • Joseph Kambeitz
    • 3
  • Dagmar Koethe
    • 6
  • Ludwig Kraus
    • 7
  • F. Markus Leweke
    • 6
  • Beat Lutz
    • 8
  • Liane Paul
    • 9
  • Oliver Pogarell
    • 3
  • Ulrich Preuss
    • 10
  • Michael Schäfer
    • 11
  • Sophia Schmieder
    • 2
  • Roland Simon
    • 7
  • Martin Storr
    • 12
  • Eva Hoch
    • 2
  1. 1.Entwicklungspsychologie und Biologische Psychologie, Psychologisches Institut der Universität HeidelbergUniversität HeidelbergHeidelbergDeutschland
  2. 2.Forschungsgruppe Cannabinoide, Klinik und Poliklinik für Psychiatrie und PsychotherapieKlinikum der Universität MünchenMünchenDeutschland
  3. 3.Klinik und Poliklinik für Psychiatrie und PsychotherapieKlinikum der Universität MünchenMünchenDeutschland
  4. 4.Klinik für Psychiatrie, Psychotherapie und Psychosomatik, Evangelisches Krankenhaus Castrop-RauxelAkademisches Lehrkrankenhaus der Universität Duisburg-EssenCastrop-RauxelDeutschland
  5. 5.Klinik für Abhängiges Verhalten und SuchtmedizinZentralinstitut für Seelische GesundheitMannheimDeutschland
  6. 6.Brain and Mind CentreThe university of SydneyCamperdownAustralia
  7. 7.IFT Institut für TherapieforschungMünchenDeutschland
  8. 8.Institut für Physiologische Chemie und Deutsches Resilienz ZentrumUniversitätsmedizin der Johannes Gutenberg-Universität MainzMainzDeutschland
  9. 9.Forensische Toxikologie, Institut für RechtsmedizinLudwig-Maximilians-Universität MünchenMüchenDeutschland
  10. 10.Klinik für Psychiatrie und PsychotherapieVITOS-KlinikHerbornDeutschland
  11. 11.Klinik für Anästhesiologie mit Schwerpunkt op. IntensivmedizinCharité – Universitätsmedizin Berlin, Campus Virchow KlinikumBerlinDeutschland
  12. 12.GesundheitszentrumMedizinisches Versorgungszentrum Gauting-StarnbergGautingDeutschland

Personalised recommendations